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T cell receptor (TCR)-based therapeutic cells and agents have emerged as a new 
class of effective cancer therapeutics against intracellular cancer-associated proteins. 
These agents rely on presentation of short peptides derived from cellular, viral or 
phagocytosed proteins on major histocompatibility complex (MHC). However, cross-
reactivities of these agents to off-target cells and tissues are poorly understood, 
difficult to predict, and have resulted in serious, sometimes fatal, adverse events. We 
have developed a mammalian, minigene-based method (termed “PresentER”) that 
encodes MHC-I peptide ligands for functional immunological assays as well as for 
determining the reactivities and potential cross-reactivities of TCR-like therapeutic 
agents against libraries of MHC-I ligands. This system is highly specific to, and 
entirely dependent on, the genetically encoded MHC peptide sequence, because it 
does not require proteasome cleavage, transporter associated with antigen 
processing (TAP) or processing, for immune presentation. Cells expressing 
PresentER antigens can be bound by TCR and TCR mimic (TCRm) antibodies, 
activate antigen-specific T cells, lead to antigen-specific cell death in vitro and tumor 
rejection in vivo. Using PresentER in a pooled library screen, we find dozens of MHC-
I ligands encoded in the human proteome that are cross-reactive with two TCR mimic 
antibodies and are not predictable by other methods. We extend the use of this 
method to find the targets of an engineered TCR.  
 
 Finally, we leverage the ability to generate tumors comprised of libraries of MHC-I 
ligands to study the determinants of MHC-I peptide immunogenicity in vivo. 
Surprisingly, we show that highly immunogenic tumor antigens (encoded by 
PresentER) do not lead to early immune-mediated tumor rejection in vivo when the 
fraction of cells bearing each antigen (“clonal fraction”) is low. Moreover, the clonal 
fraction that must bear an antigen in order to lead to rejection of immunogenic tumor 
subclones is dependent on the individual antigen itself. These data indicate that 
tumor neoantigen heterogeneity has an underappreciated impact on the ability of the 
immune system to detect and eliminate cancer cells and has implications for the 
prioritization of antigens in the design of novel antigen-specific immunotherapeutics 
such as cancer vaccines.  
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BIOGRAPHICAL SKETCH 
Ron was born in Rockville, Maryland to Argentine parents: a physician-scientist father 
and a Jewish educator mother. His father inculcated in Ron an early interest in logic 
and philosophy and later science and medicine. Beginning at the age of 11-12, Ron 
taught himself how to program computers, which opened an avenue by which to do 
scientific research while in high school. His father helped him secure a mentored 
summer position with Dr. Maria Martinez working on tools to analyze genome-wide 
association studies. He continued onto Columbia University for his Bachelor of Arts, 
starting in 2006 and double majoring in Philosophy and Biology. During college, he 
became very interested in RNA, a molecule which is at the very center of molecular 
biology, and worked in the laboratory of Dr. Lawrence Chasin for 3 years studying the 
regulation of RNA splicing using publically available DNA and RNA sequencing data. 
The explosion of data from the human genome project and other large data-collection 
projects meant that there were many questions that could now be asked and 
answered by just querying datasets online, without having to lift a pipette, but with the 
caveat that data could be wrong or biased in unanticipated ways. Of all of that Ron 
learned from Dr. Chasin’s lab, the most critical were how to design simple 
experiments to test an incisive question and how to consider and deal with 
confounders when analyzing large data. In 2010, after graduating from college, he 
worked for one year in the laboratory of Dr. Alexander Tarakhovsky studying 
chromatin biology using ChIP-Seq and running the lab’s Illumina HiSeq. Ron became 
enthralled with the immune system as a model system within which to learn about all 
major principles in biology, from molecular concepts to the organization of large 
numbers of cells into tissue. With access to a HiSeq pumping out massive amounts of 
DNA sequences every week, he realized that his training in computational biology 
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made him uniquely well suited to do “high throughput” biology for discovery and 
therapeutic purposes.  
 
Ron decided to pursue an MD/PhD at the Weill Cornell Medical College / Rockefeller 
University / Memorial Sloan Kettering Cancer Center Tri-Institutional MD/PhD 
program, matriculating in 2011. He began his PhD in Dr. David Scheinberg’s lab and 
became fascinated with peptide antigen presentation and immunogenicity, trying to 
understand why certain mutations made cancer cells recognizable to the immune 
system and other did not. The combinatorial problem posed by immune discrimination 
between altered/foreign and self-peptides was the subject of Ron’s interests for the 
next 5 years. He became excited by the possibility of harnessing the immune 
system’s tools to selectively kill cancer cells on the basis of altered peptide ligands 
they present on the surface of their cells was, but he recognized that it would be 
difficult to ensure these drugs were safe before they were given to a person. 
Therefore, he developed a method to express libraries of peptide-MHC molecules in 
mammalian cells and applied this approach to systematically identify ligands of 
cancer therapeutics that might make them unsafe to give to humans. He then turned 
to the study of immunogenicity in vivo models of cancer to try and ask and answer his 
original question: what are the characteristics of immunogenic MHC-I neoantigens? 
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INTRODUCTION 
 
The basic premise of cancer therapy is to kill cancer cells while sparing normal cells. 
The simplicity of this premise is belied by the difficulty of finding cellular 
characteristics that both efficiently distinguish cancerous from normal cells and can 
be effectively targeted by therapeutic agents. While cancer cells differ from other cells 
in many respects, most of the differences are found within the intracellular space, and 
thus inaccessible to most potential therapeutics (from small molecules to antibodies 
to engineered cells). In response to the challenge of developing molecules that can 
cross the cellular plasma membrane, recent successful cancer therapeutics have 
focused on the small subset of proteins that are found on the surface of cancer cells1. 
However, the past 50 years have shed light on a generalized molecular mechanism 
found in all nucleated cells that exposes fragments of cellular proteins on the surface 
of the plasma membrane2. The discovery of this mechanism, now called antigen 
presentation, has ushered in a new paradigm in the treatment of cancer and will be 
the subject of this dissertation. 
 
The Major histocompatibility complex (MHC) is a cell-surface protein that is 
assembled in the endoplasmic reticulum together with beta-2-microglobuin (β2M) and 
a short, variable protein fragment. In humans, MHC molecules are also referred to 
Human leukocyte antigen (HLA). The protein fragment (peptide) is noncovalently 
embedded in the groove of the MHC/β2M complex and the entire complex is exported 
to the surface of the cell. The peptides presented on MHC are derived from 
proteolytic cleavage of many cellular proteins, thus thousands of distinct peptide-
MHC (pMHC) can be found the plasma membrane3,4. There are two flavors of MHC 
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molecules: MHC-I, which is found on all nucleated cells and generally presents 8-11 
amino acid peptides and MHC-II, which is found primarily on specialized antigen 
presenting cells such as dendritic cells, macrophages and B cells. MHC-II molecules 
presents longer peptides up to about 20 amino acids long5. 
 
 
Figure 1 Structure of HLA-A*02:01 with peptide. The structure of HLA-A*02:01 in 
complex with beta-2-microglobulin and a peptide from the Human T-lymphotropic 
virus type I (HTLV-1) Tax (11-19) LLFGYPVYV. Structures downloaded from the 
RCSB Protein Data Bank6 ID # 1AO77 
There is tremendous genetic variability at the MHC locus in the human population, 
affecting the size, shape and biochemical characteristics of the presented peptides. In 
the human genome there are three classical MHC-I genes: HLA-A, HLA-B and HLA-
C. Across all three of these genes there are >13,000 known alleles (as of July, 
2018)8. As a diploid organism, humans can express as few as three and as many as 
six distinct classical MHC-I alleles. The complete repertoire of peptides that are 
presented on a human cell is based on an individual’s genetic diversity at the MHC 
locus as well as the genes expressed by that cell. For instance, the most common 
MHC-I allele in the Caucasian population of the United States is HLA-A*02:01, which 
typically binds and presents peptides of 9 amino acids in length with hydrophobic 
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amino acids in the 2nd and 9th position (Figure 2). Another common allele, HLA-
A*24:02 binds preferentially to peptides with a Y/F/W/M in the 2nd position and a F/I/L 
in the 9th position. Thus, a person that is homozygous for HLA-A*02:01 will present 
different peptides from a person who is homozygous for HLA-A*24:02. It is not only 
the motif of peptides presented on HLA that differs by allele, but also the repertoire 
size, affinity diversity of peptides presented by each HLA allele9. 
 
 
Figure 2 HLA-A*02:01 peptide binding motif. The MHC-I molecule HLA-A*02:01 
typically binds linear peptides with hydrophobic amino acids in the 2nd and 9th 
position. This motif was generated using NetMHCPan v4.0 based on known HLA-
A*02:01 ligands. 
Cell state and health can dramatically change the repertoire of presented peptides. 
For instance, infection with a virus leads to presentation of peptides derived from viral 
proteins, in addition to the endogenous peptides that are normally presented10. A 
general principle is that the most abundant peptides found on surface MHC are those 
with high affinity to the MHC molecule and encoded by highly transcribed and 
translated genes11. Indeed, low affinity peptides can be replaced with higher affinity 
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peptide using TABPR, which displaces low affinity peptides and stabilizes empty 
MHC molecules until a higher affinity ligand is found12.  
 
MHC presented peptides (pMHC) are announcements to the immune system about 
which proteins are expressed within the cell. For instance, cells infected with 
intracellular pathogens (viruses, mycobacteria) will express foreign proteins and their 
proteolytic degradation may yield MHC ligands. T cells that recognize the foreign 
peptides displayed on the cell can activate and kill the infected cell. The general 
principle by which T cells recognize target cells is through engagement of the T cell 
receptor (TCR) on the pMHC. Each T cell develops a distinct, semi-randomly 
generated TCR while they mature in the thymus. T cells bearing non-functional TCRs 
or TCRs that bind to self-peptides presented on MHC are clonally deleted while T 
cells with functional, non-auto-reactive TCRs are permitted to leave the thymus. T 
cells that encounter a cognate pMHC antigen can, given the appropriate cytokines 
and contextual cues, activate, proliferate and kill cells bearing the foreign pMHC. 
 
The diversity of T cells and the genetic heterogeneity of peptide-MHC is thought to 
reflect an evolutionary arms race between pathogens and organisms with an adaptive 
immune system. In brief, populations of pathogens are continuously infecting 
populations of mammals and evolving to escape from the immune system. In turn, 
mammals have developed high levels of genetic heterogeneity at the MHC locus in 
order to prevent the emergence of pathogens with protein sequences that cannot be 
bound by any MHC allele in the population. Individuals carrying multiple genetically 
dissimilar MHC-I alleles can present a broader range of all possible short peptides13, 
and are thus theoretically more resilient to pathogens. In order to recognize and kill 
cells expressing foreign MHC-I peptides, mammals have evolved the ability to 
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generate an enormous and diverse T cell repertoire where each T cell can 
theoretically recognize a different pMHC. A structure of a TCR in complex with its 
target peptide presented on MHC-I is shown in Figure 3. 
 
 
 
Figure 3 Structure of the TCR-peptide-HLA ternary complex. The structure of the 
A6 TCR bound to a peptide from the Human T-lymphotropic virus type I (HTLV-1) Tax 
(11-19) LLFGYPVYV presented on HLA-A02:01. Structure downloaded from the 
RCSB Protein Data Bank6; ID # 1AO77 
 
The diversity of distinct pMHC that can be recognized by T cells allows T cells to 
respond to nearly all pathogens that might enter the organism, including those that 
have never been seen before. However, there is an upper limit to the number of T 
cells found in any individual. Humans are estimated to have ~1012 T cells, but this 
number is several orders of magnitude lower than the number of possible MHC-I and 
A B
C
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MHC-II ligands. In order to deal with the enormous diversity of possible target 
sequences, TCRs are cross-reactive14-16. A single TCR is estimated to be capable of 
binding to 1 million distinct pMHC16. The risk that such a degenerate system of 
pathogen recognition poses is that a T cell may bind to both a pathogenic peptide as 
well as a self-peptide, thus activating in response to a pathogen, but also causing 
autoimmune disease. In practice, widespread cross-reactivity does not lead to 
autoimmune disease because most autoreactive T cells are clonally eliminated during 
T cell development in the thymus17,18. Autoreactive T cells that escape the thymus 
can be rendered nonfunctional by several mechanisms; for instance, if they do not 
receive the appropriate contextual cues (“danger signals”) at the same time as they 
encounter their cognate antigen. 
 
T cells are not restricted to the recognition and killing of cells infected with pathogens. 
They can also recognize cancer cells when those cells display mutated peptides or 
overexpressed cancer-specific self-peptides. T cells found within tumors can 
recognize somatic mutation-derived neoantigens expressed and presented by tumor 
cells. T cells that recognize neoantigens have even been used to successfully treat 
patients. One approach that has been used is transfer of autologous tumor infiltrating 
lymphocytes (TILs) into patients. Briefly, this is done by harvesting tumor infiltrating 
lymphocytes (TILs), expanding them ex vivo and re-infusing them into patients19-21. 
While successful in some cases, TIL based therapies are patient-specific, costly and 
efficacy is difficult to evaluate because each patient receives a different 
“personalized” treatment. An alternative approach is to target “universal” cancer-
specific pMHC that are found across many different patients and tumor types. Many 
therapies directed towards these universal pMHC targets have been developed, 
including T cells expressing engineered TCR22-24 or antibodies that mimic the 
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structure of TCR (TCRm)25-28. Engineered TCR and TCR mimic antibodies are more 
cost effective and easier to test in clinical trials because they do not vary from patient-
to-patient. For instance, Wilms Tumor 1 (WT1) is a protein that is widely expressed in 
cancers but only expressed in a minority of normal tissues. HLA-A*02:01+/WT1+ cells 
express a specific WT1-derived pMHC on the surface: RMFPNAPYL. Several 
RMFPNAPYL/HLA-A*02:01 specific therapeutic drugs have been developed, 
including T cells expressing affinity matured TCRs29 and antibodies that have been 
selected to bind to this pMHC (TCR mimic antibodies)30.  
 
Figure 4 presents a schematic of how MHC presented peptides are generated and 
interact with therapeutic agents such as T cells and TCR mimic antibodies. 
 
 
Figure 4 MHC-I antigen presentation and antigen recognition by T cells and 
TCR like molecules. Cancer cells can present cancer-specific peptides on the 
surface that can be bound to by T cells and TCR like molecules such as TCR mimic 
antibodies. Reprinted from Chang et al25. 
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Whether an MHC-I molecule is presenting a viral peptide or a self-peptide, the vast 
majority of the binding surface presented to a T cell is identical. The only region of the 
MHC that is “specific” and thus marks a cell as virally infected or as a cancer is the 
linear peptide found in the MHC groove. The groove is the region of the complex to 
which TCRs bind (Figure 3) and TCR specificity is generated by engaging with the 
residues of the peptide that face “up” from the MHC groove. The same MHC-derived 
structural constraints apply to other biologic molecules that engage with MHC 
presented peptide. For instance, an antibody that binds to a specific peptide 
presented on MHC must engage primarily with the upward facing residues of the 
peptide. If it binds too strongly to the invariant portion of the MHC then it will 
necessarily be cross-reactive. Thus, although TCRs are low affinity (µM), cell-
anchored and monovalent (one TCR binds to one epitope) whereas antibodies are 
soluble, high affinity (nM) and bivalent (one antibody binds to two identical targets), 
the mechanism by which they must recognize their target is very similar.  From the 
perspective of the total binding surface, two different peptides presented on HLA-
A*02:01 are highly similar. This is in contrast to traditional antibody targets, where 
epitopes from distinct proteins are typically dissimilar. Thus, making therapeutic 
antibodies against a traditional, extracellular or soluble target protein is a significantly 
less challenging than making a TCR like molecule that is specific to a single 
presented MHC-I peptide. 
 
TCR-based therapeutics that do not undergo negative selection for the human pMHC 
repertoire or are further engineered for high affinity binding can be auto-reactive. A 
prominent example is an affinity-enhanced engineered T cell directed towards the 
MAGE-A3 peptide HLA-A*01:01/EVDPIGHLY, which induced lethal cardiotoxicity in 
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two patients during a phase I clinical trial. Although this TCR was originally located in 
a human, it was modified in vitro to increase its affinity for the MAGE-A3 peptide. 
Extensive preclinical testing failed to uncover off-target reactivity of the anti-MAGE 
TCR, but afterwards it was discovered that an epitope derived from the Titin protein (a 
structural protein highly expressed by cardiomyocytes), was cross-reactive with the 
MAGE-A3 TCR (HLA-A*01:01/ESDPIVAQY)31. Hence, a major challenge to the 
development of safe TCR based therapeutics is the prospective identification of off-
tumor off-targets25. 
 
In mammals, an entire organ (the thymus) is used to eliminate auto-reactive T cells. 
However, for drug developers, there is no currently available mechanism to negatively 
select TCR like therapeutic molecules during drug development. We cannot yet 
screen a candidate TCR drug against a wide range of target epitopes to identify 
cross-reactivities. For traditional antibodies, this is acceptable because antibodies are 
not as likely to be cross reactive as TCR mimic antibodies and because antibodies 
can be tested for safety in animals (where protein homology means that at least some 
cross-reactivities will be detected) as well as in dose-escalation clinical trials in 
humans. However, TCR-like molecules, which are likely to be cross-reactive against 
unknown antigens presented on human-specific MHC molecules for the reasons 
specified above, cannot easily be tested in animal models because they will not bind 
to non-human MHC. Moreover, although TCR-like monoclonal antibodies can 
theoretically be dose-escalated to evaluate toxicity, TCR mimics of this format have 
not yet been used in clinical trial. The only TCR-like molecules that have gone into 
humans are native or affinity matured T cell receptors that have been heterologously 
expressed in donor-patient T cells and infused into patients, where they undergo 
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rapid clonal expansion and are thus not easily tested for safety by dose-escalation 
studies. 
 
Identifying off-tumor, off-targets of TCR like therapeutics is challenging for three 
reasons: (1) the scope and extent of the repertoire of MHC ligands in humans is 
unknown, despite multiple reports of isolation by mass spectrometry, (2) cross-
reactive pMHC are not readily predictable from crystal structures or alanine scanning 
and (3) animal models of cross-reactivity are not possible due to the species-specific 
peptide processing32 and structure of MHC. Methods to search the MHC-I ligandome 
for TCR targets have been developed with yeast33,34, insect-baculovirus35 and 
tetramer36,37 technologies. These systems are powerful because billions of MHC-I 
ligands can be encoded by a population and used to find cross-reactivities—and they 
have been successfully used to discover cross-reactive targets of some TCRs, in 
addition to elucidating fundamental biology of TCRs38. However, the cellular systems 
use a synthetic covalent linker to enforce peptide-MHC proximity, which allows 
presentation of peptides that would not ordinarily be presented and may distort the 
structure of the epitope. The tetramer-based screening systems rely on peptide 
synthesis, which is expensive and time consuming. Furthermore, tetramer, yeast and 
insect systems cannot be used for in vitro and in vivo immunology assays, such as 
those that measure T cell activation and cytotoxicity.  
 
The first chapter of this dissertation deals with the development of a method, termed 
“PresentER,” to express single peptide-MHC in mammalian cells and enable 
screening of TCR and TCR like molecules against thousands of possible off-target 
peptides. The second chapter of this dissertation establishes that PresentER 
encoded antigens can be used to study tumor immunology in vivo using 
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immunocompetent animal models to discover the determinants of peptide 
immunogenicity.  
Chapter I: Development of an MHC-I peptide presentation system 
Introduction 
The number of endogenous MHC-I ligands that are theoretically presentable in 
human tissue is enormous. Using an in silico digest of the human proteome and the 
MHC-I ligand predictor NetMHCPan, over 750,000 peptides of 9 and 10 amino acids 
in length are predicted to bind to HLA-A*02:01 (ic50 < 500nM). Over the thousands of 
MHC-I alleles found in the human population, many of which have slight variations on 
the peptides they present, the number of peptides that can be presented increases 
dramatically. However, not all peptides that are predicted to bind to MHC-I in silico will 
be found on the surface of a cell. For instance, some peptides are cleaved in the 
middle by the proteasome or immunoproteasome25, inefficiently transported by TAP38, 
found in low abundance10,39, or are never generated in the first place because they 
are not cleaved at the C-terminus38. Some peptides are generated by the proteasome 
and bind to MHC, but are replaced with higher affinity peptides in the ER by the 
“peptide editor” TAPBPR11. 
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Figure 5 Cumulative number of predicted HLA-A*02:01 peptides across the 
human proteome. The complete human proteome downloaded from UniProt (May, 
2017) was digested in silico into 9mer and 10mer peptide sequences. The predicted 
affinity to HLA-A*02:01 was calculated with NetMHCPan v4.0 and the cumulative 
number of peptides predicted to bind at each affinity is plotted. Affinities are 
represented as 50% inhibitory concentrations. Lower ic50s are higher affinity. A 
dashed line at 500 nM indicates the empirically determined cut-off for HLA-A*02:01 
binding. 
 
Major advances have been made in the past few years to identify the MHC-I ligands 
that are actually presented on human cells. The general approach taken is to 
immunoprecipitate HLA complexes from isolated plasma membranes using an 
antibody that binds HLA and disassociate the peptides from MHC by acid washes. 
The eluted peptides are chromatographically separated and subject to tandem mass 
spectrometry. This approach has led to the discovery of hundreds of thousands of 
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presented peptides across all major HLA types4,10,40-42. However, it remains unclear 
how many presented peptides remain to be discovered. In other words: the actual, 
complete ligandome of MHC-I peptides is unknown. Moreover, little is known about 
the antigens presented on important tissues where access is limited: brain, eye, 
heart, etc. These tissues may present peptides which can cross-react with TCR 
therapeutics. Another challenge is determining the ligandome of cells present in low 
abundance (e.g. retina). Thus, until there is more confidence that the complete 
repertoire of presented human peptides is known, it remains difficult and work-
intensive to ensure that a TCR like therapeutic molecule will not cross-react with an 
endogenously expressed and presented pMHC. Indeed, large numbers of peptides 
that are derived from human proteins and predicted to bind to MHC-I must currently 
be tested to be relatively certain that a cross-reactive peptide is not found.  
 
The classical method used to validate that a TCR like therapeutic molecule is specific 
to its target is to assay its binding to a small number of rationally selected off-targets. 
First, a small number of peptides are synthesized in order to determine where the 
TCR like molecule binds along the linear peptide target. Generally, each of these 
peptides differs from the target peptide by a single amino acid substitution. For 
instance, each amino acid can be replaced with an alanine (also known as an 
“alanine scan”). These peptides are resuspended in an amphipathic solvent such as 
DMSO and pulsed at molar excess onto TAP deficient cells (e.g. 500µM) together 
with soluble beta-2-microglobulin, where they displace the peptides found on the 
MHC and allow refolding with the new peptide to occur44. This is known as “peptide 
pulsing” or alternatively “MHC stabilization assay” because the peptide stabilizes 
MHC on the surface of the cell, leading to an increase in the total amount of surface 
MHC44. Based on the peptide variants that bind to the TCR like molecule or activate T 
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cells expressing the TCR like molecule, new sets of peptides are designed to probe 
the specific residues that are of functional importance to the binding. The cost to 
synthesize individual peptides at microgram scale is ~$7-10 per amino acid ($70-
$100 per peptide). Therefore, testing even a few peptides quickly becomes cost 
prohibitive. As a result, most evaluation of off targets is through assessment of 
binding/activation to accessible normal tissue, cell lines that do not express the target 
gene and a small number of synthesized peptides designed to elucidate where the 
therapeutic agent binds to the peptide. These relatively low-throughput and 
information-poor approaches cannot approach the breadth of possible off targets 
encoded in the human proteome. 
 
We hypothesized that we could identify large numbers of off-target MHC-I ligands by 
screening reactivity of TCR like therapeutic molecules to cells expressing DNA 
barcoded, peptide-minigenes. Building off of the work of others who have used 
antigen minigenes to express MHC-I ligands in mammalian cells45-47, we developed a 
minigene vector called “PresentER” that encodes MHC-I ligands downstream of an 
endoplasmic reticulum signal sequence. We chose a long signal sequence in order to 
avoid nonsense-mediated decay of the short messenger RNA. By cloning the precise 
MHC-I ligand downstream of an endoplasmic signal sequence, the minigene encoded 
peptides do not need to be cleaved by the proteasome, transported by TAP or 
trimmed by aminopeptidases in order to be loaded onto MHC-I and presented on the 
surface of the cells. MHC-I peptides are short (8-11 amino acids), thus the DNA 
encoding the peptide serves as the barcode which can be re-identified by sequencing 
the minigene itself.  
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We have previously isolated and characterized two TCR mimic (TCRm) antibodies 
(ESK130 and Pr2026), which bind to the HLA-A*02:01 ligands RMFPNAPYL 
(WT1:126-134), and ALYVDSLFFL (PRAME:300-309), respectively. WT1 and 
PRAME are over-expressed across many cancer types but not expressed widely on 
normal tissue. WT1 is expressed in some developing tissues during embryogenesis, 
as well as in the adult urogenital system central nervous system and the 
hematopoietic system52. PRAME is also expressed in some normal tissues such as 
placenta, adrenal glands, ovaries and endometrial lining53. Despite this, WT1 remains 
one of the top National Cancer Institute targets for cancer therapy48 and PRAME 
remains a major target for investigational cancer therapeutics55. TCR mimic 
antibodies against WT1 and PRAME were selected by panning a pool of phage 
displaying the variable region of antibodies called Fragment antigen binding (Fab) 
against soluble MHC-I complexes containing RMF or ALY peptides. The two TCR 
mimics that were selected were cloned into monoclonal antibody expression vectors 
and the purified monoclonal antibody underwent extensive pre-clinical testing to test 
for specificity to the target epitopes. Cross-reactive ligands of both ESK1 and Pr20 
were discovered through alanine scanning and evaluation of a small number of 
candidate off-target peptides26,49.  In order to identify if any cross-reactive ligands of 
ESK1 or Pr20 would compromise the ability to use these drugs in humans, we 
screened thousands of peptides found in the human proteome to identify those that 
might bind to ESK1 or Pr20. 
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Materials and Methods 
Cloning PresentER Cassette and PresentER constructs 
The Mouse Stem Cell Virus vector that is the basis of the PresentER cassette was a 
generous gift from Scott Lowe of the Lowe lab. The 98-amino acid ENV_MMTVC 
signal peptide from Mouse Mammary Tumor Virus envelope protein (accession 
#Q85646) was found in the Signal Peptide Database 
(http://www.signalpeptide.de/index.php). IDT gBlocks encoding a modified, human 
codon optimized signal sequence followed by an antigen and a stop codon were 
ordered and cloned into the MLP vector with XhoI and EcoRI. The modifications 
changed two amino acids to enable directional cloning with the SfiI restriction 
enzyme: …PQTSLTLFLALL[S>A]VL[G>A]PPPVSG. A cassette with an SfiI site at 
the 3’ end was also included in the gBlock and this construct is collectively termed the 
PresentER Cassette. In order to clone antigens into PresentER, DNA sequences 
encoding individual antigens were ordered from IDT, amplified with PresentER-F and 
PresentER-R primers and digested with SfiI. Digested inserts were purified with the 
Qiagen MinElute kit to remove primer dimers. The PresentER Cassette was digested 
with SfiI, treated with Calf Intestinal Phosphatase and gel purified. The inserts were 
ligated into the digested PresentER backbone with T4 ligase (NEB Catalog #M0202) 
and transformed into NEB Stable cells (NEB Catalog #C3040). All sequences can be 
found in the table of DNA and protein sequences. The PresentER cassette and 
several example PresentER minigenes are available on Addgene (e.g. Plasmid 
#102944, #102945, #102943). 
 
Production of retrovirus and transduction of cells 
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HEK293T Phoenix amphoteric cells were transfected with polyethylenimine (PEI) and 
PresentER plasmid (15µg DNA : 45µg PEI) in 10cm TC plates. Virus was harvested 
every 12 hours, pooled, concentrated with Clontech Retro-X (Cat. #631455) and 
frozen in aliquots. T2 cells were spinoculated with virus in non-TC treated 6-well 
plates at 32ºC x 2,000xg for 2 hours with 4µg/ml of polybrene. RMA-S cells were 
spinoculated with virus in non-TC treated 6-well plates at 32ºC x 1,000xg for 2 hours 
with 4µg/ml of polybrene.  Library retrovirus was produced in the same way, except 
that virus production was scaled up to four 15cm plates per library. The volume of 
viral supernatant that led to 1/3 maximal transduction efficiency was established for 
each batch of virus produced. Transduced cells were selected with 1µg/ml (T2) or 
4µg/ml (RMA-S) of puromycin for 2-3 days until cells were >95% GFP positive. 
 
Antibodies and commercial reagents 
ESK1 and Pr20 antibodies were purified by Eureka Therapeutics and fluorescently 
labeled using Innova Biosciences lightning link kits (705-0010). Each labeled aliquot 
was titered on T2s or RMA-S cell bearing the PresentER minigenes. The TCR 
multimer specific to NLVPMVATV (CMV aa495-503)/HLA-A2.1 was purchased from 
Altor BioScience (Cat #TCR-CR1-0020). APC labeled antibodies specific to 
SIINFEKL/H2-Kb (Clone 25-D1.16) were purchased from Ebioscience (Cat #141606). 
 
Generation of AviTagged A6 TCR 
The A6 TCR was a generous gift from Brian Baker’s lab. The beta chain plasmid was 
modified to encode a C-terminal AviTag biotinylation site (GLNDIFEAQKIEWHE). The 
site was inserted using Gibson cloning and following two primers: F: 5’-
gcagaaaattgaatggcatgaaTAAGCTTGAATTCCGATCCGG-3’ R: 5’-
gcttcaaaaatatcgttcaggccGTCTGCTCTACCCCAGGC-3’. Both the alpha and beta 
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chain were expressed in BL21 (DE3) bacteria and induced with 1mM IPTG. The beta 
chain was co-expressed with a plasmid encoding the BirA enzyme (Addgene #26624) 
and supplemental biotin (0.5mM D-Biotin). Inclusion bodies were harvested and the 
individual chains were purified and re-folded together according to previously 
described protocols50,51. 
 
Cloning the PresentER Library 
A pool of 12,472 oligonucleotides was synthesized by CustomArray, Inc in the 
following format: 5’- GGCCGTATTGGCCCCGCCACCTGTGAGCGGG…[27-30nt 
insert]…TAAGGCCAAACAGGCC-3’. The oligonucleotides were cloned into the 
PresentER vector in exactly the same way as the individual minigene. After ligation, 
the ligation products were electroporated into competent cells and plated onto four 
15cm ampicillin-LB plates. After overnight growth, the number of colonies was 
estimated to be ~46x106. The colonies were scraped off the plate and grown for 3.5h 
in TB + ampicillin at 37ºC at 225rpm. The bacteria were maxiprepped and library 
representation was checked by Illumina sequencing.  
 
Library screening by FACS 
T2 cells transduced with library virus or single-minigene controls were stained with 
ESK1-APC or Pr20-APC. Sorting gates were set-up based on the fluorescence of the 
stained single-minigene control cells (PresentER-RMF and PresentER-ALY). Each 
sort was performed two times for each antibody. Sorted cells were frozen for genomic 
DNA extraction and Illumina sequencing. Pre-sort (“unsorted”) cells were frozen as 
well. 
 
Genomic DNA Extraction and Library Sequencing 
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Genomic DNA was extracted from unsorted or sorted cells with the Qiagen Gentra 
Puregene kit (Catalog #158667). Genomic DNA was amplified with barcoded primers 
and sequenced by the Integrated Genomics Operation core at MSKCC. 
 
Bioinformatics 
The peptides included in the PresentER library were found in Uniprot TrEMBL 
database of reviewed and unreviewed human protein sequences. Substrings of 
unique 9 and 10 amino acid sequences were derived from this databaset and affinity 
to HLA-A*02:01 was calculated using NetMHCPan. Peptides with predicted 
ic50<500nM were compared to the ESK1 and Pr20 cross-reactivity motifs to 
determine which should be included in the library (Figure 14). All potentially cross-
reactive ESK1 ligands and half of the potential Pr20 ligands were included in the 
library. 
 
After Illumina sequencing, reads were mapped to the PresentER minigene library with 
Bowtie2. Reads that did not map to the minigenes in the library were discarded. Data 
analysis was performed in R. In order to identify minigenes encoding antibody 
ligands, we normalized the abundances in the sorted samples by the abundances in 
the unsorted samples and then divided the abundance of each minigene in the 
“antibody high” sample by the abundance of each minigene in the “antibody low” 
sample. 
 
Screen validation by peptide pulsing 
Spot synthesized peptides (PepTrack libraries) were ordered from JPT Peptide 
Technologies. Peptides were resuspended to 20mg/ml in DMSO, followed by dilution 
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to 1mg/ml in PBS and finally pulsed onto T2 cells at 50µg/ml. Pulsed cells were 
stained with ESK1 or Pr20 to evaluate binding of antibody to pMHC. 
 
Evaluation of ESK1 binding to JY and TPC1 
JY and TPC1 cells were stained with unlabeled ESK1 or IgG1 isotype control 
(BioLegend Cat #ET901) followed by anti-human IgG1 APC antibody (BioLegend Cat 
#HP6017). 
 
Generation of T cells with transgenic TCR 
MSGV-1 plasmids encoding the DMF5 and 1G4 TCRs were provided as a kind gift 
from Dr. Steven A. Rosenberg. Plasmids encoding A6 and B7 TCRS were generated 
as described above. TCR retroviral transduction was performed as described 
previously52. Briefly, retroviral particles were generated by transient transfection of the 
retroviral packaging cell line 293GP cells with the pMSGV1-TCR plasmids and 
pRD114 plasmid using Lipofectamine 2000 (Life Technologies). Retroviral 
supernatant was harvested 2 days later, and used to transduce PBMC that were 
stimulated with soluble 50 ng/ml anti-CD3 (OKT3, Miltenyi Biotec) and 300 IU/ml rhIL-
2 (Chiron) for 2 days prior to retroviral transduction. Retroviral transductions were 
performed on Retronectin (Takara) coated non-tissue culture treated 24-wells plates 
by spinoculation of the retrovirus at 2,000× g, 32°C for 2 hours, followed by addition 
of activated T cells to the retrovirus containing plates. Following overnight incubation 
at 37°C, 5% CO2, T cells were transferred to a tissue-culture treated 24-wells plate 
and expanded in T cell media supplemented with 300 IU/ml rhIL-2 (Chiron). 
Transduced T cells were used at 10-15 days post-transduction or cryopreserved until 
used in assays. 
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Generation of A6 and B7 TCR mammalian expression plasmids 
The bacterial expression vectors for production of non-membrane bound (soluble) A6 
and B7 TCRs were cloned with Gibson Assembly into the MSGV-1 mammalian 
expression (retroviral) vector. MSGV-1 vector encoding 1G4 was used as the vector 
backbone and the intergenic sequence between the 1G4 alpha and beta chains were 
cloned in between the alpha and beta chains of A6 and B7. A gBlock encoding the 
common N-terminus of A6, B7 and 1G4 was ordered 
(MKSLRVLLVILWLQLSWVWSQ): 5’-
CGCAGCTTGGATACACGCCGCCCACGTGAAGGCTGCCGACCCCGGGGGTGGA
CCATCCTCTAGACCGCCATGAAGTCTTTGCGCGTACTCTTGGTGATATTGTGGCT
CCAATTGAGTTGGGTGTGGTCCCAG-3’.  An additional 2 gBlocks were ordered for 
the A6 beta chain (5’- 
CGGCCAGGTCTTGCCGGGGGACGACCAGAGCAGTATTTCGGGCCAGGGACGC
GCCTTACGGTAACAGAAGACTTGAAGAATGTCTTTCCACCTGAGGTCGCCGTTTT
TGAACCCTCCGAGGCCGAAATAAGTCATACTCAAAAGGCGACTCTGGTGTGCCT
CGCCACCGGGTTTTACCCGGACCACGTAGAACTTAGCTGGTGGGTGAATGGTAA
AGAGGTCCATAGCGGGGTGTGCACGGACCCACAGCCTCTCAAGGAACAACCCG
CTCTGAATGATTCCAGGTATTGTCTTAGCTCACGGCTTCGAGTGTCAGCTACTTT
TTGGCAAGAT-3’ and B7 beta chain (5’- 
AGTTACCCTGGAGGAGGCTTTTATGAGCAGTATTTCGGTCCTGGAACAAGGCTG
ACCGTGACGGAAGATTTGAAAAATGTCTTTCCCCCAGAGGTAGCAGTCTTCGAG
CCGTCCGAGGCCGAGATATCCCATACCCAGAAGGCAACCCTTGTTTGCTTGGCA
ACGGGATTTTATCCAGATCATGTGGAATTGTCCTGGTGGGTCAACGGCAAAGAG
GTTCACAGCGGCGTCTGCACAGATCCGCAACCACTCAAGGAACAGCCCGCTCTT
AATGATTCTCGCTACTGTCTGAGTTCCAGGTTGCGGGTCAGCGCTACTTTCTGG
CAGGAT-3’):  The following fragments were PCR amplified and then assembled:  
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# Fragment 
name 
Template 
DNA 
F Primer 
Name 
F primer 
sequence 
R primer 
Name 
R primer 
sequence 
A1 N terminus 
of A6 Alpha 
chain 
A6B71G4 
Alpha chain 
N terminal 
gblock 
A6B7Oligo2 ccctcaaagtagacggcat
cCGCAGCTTGGAT
ACACGC 
A6Oligo3 cttccttctgCTG
GGACCACA
CCCAACTC 
B1 N terminus 
of B7 Alpha 
chain 
A6B71G4 
Alpha chain 
N terminal 
gblock 
A6B7Oligo2 ccctcaaagtagacggcat
cCGCAGCTTGGAT
ACACGC 
B7Oligo3 cattcttctgttgC
TGGGACCA
CACCCAAC
TC 
A2 A6 alpha 
chain 
A6 alpha A6Oligo4 gtggtcccagCAGAAG
GAAGTGGAGCAG 
A6Oligo5 tgacatcacaG
GAACTTTCT
GGGCTGGG 
B2 B7 alpha 
chain 
B7 alpha B7Oligo4 gtggtcccagCAACAG
AAGAATGATGACC
AGCAAG 
B7Oligo5 tgacatcacaA
GAGCTTTC
CGGGCTCG
G 
A3 pGMT7 
region in 
between 
chains for 
A6 
1G4 A6Oligo6 agaaagttccTGTGAT
GTCAAGCTGGTC 
A6Oligo7 gacctggccgG
CTGGCACA
GAAGTACA
C 
B3 pGMT7 
region in 
between 
chains for 
B7 
1G4 B7Oligo6 ggaaagctctTGTGAT
GTCAAGCTGGTC 
B7Oligo7  cagggtaactG
CTGGCACA
GAAGTACA
C 
A4 A6 beta 
chain 
fragment 
gBlock 
A6betachai
nfrag 
A6Oligo8 ctgtgccagcCGGCCA
GGTCTTGCCGGG 
A6Oligo9 cagcggaagtg
gttgcggggAT
CTTGCCAA
AAAGTAGC
TGACACTC
GAAGC 
B4 B7 beta 
chain 
fragment 
gBlock 
B7betachai
nfrag 
B7Oligo9 ctgtgccagcAGTTAC
CCTGGAGGAGGC 
B7Oligo1
0 
cagcggaagtg
gttgcggggAT
CCTGCCAG
AAAGTAGC 
5 Backbone 1G4 A6B7Oligo1 GATGCCGTCTACT
TTGAG 
A6B7Olig
o10 
CCCCGCAA
CCACTTCC
GC 
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ELISPOT and co-culture assay 
IFN-gamma release ELISPOTs were performed in 200µl of RPMI supplemented with 
5% FBS. 50,000 transduced T cells were incubated at the indicated effector:target 
(E:T) ratios (typically 1:1) with T2 cells expressing PresentER peptides as targets. 
Co-culture assays were performed in a similar manner: 50,000 T cells were incubated 
with 50,000 target cells per well of a U-bottom plate and the remaining cells were 
analyzed by flow cytometry to evaluate specific lysis of target cells. 
 
Data Availability 
Sequencing data for each of the experiments has been deposited: 
 
Minigene sequencing of sorted T2 cells expressing a library of HLA-A*02:01 exomic 
peptides. Cells are sorted for high and low binding of the TCR mimic antibody ESK1. 
DOI:10.5281/zenodo.1313110 
Minigene sequencing of sorted T2 cells expressing a library of HLA-A*02:01 exomic 
peptides. Cells are sorted for high and low binding of the TCR mimic antibody Pr20 
DOI:10.5281/zenodo.1326544 
Minigene sequencing of T2 cells expressing a library of off targets (derived from A6 
and B7 binding motifs in Hausmann 1999) after co-culture with A6, DMF5 or 1G4 
expressing T cells (from a non-A2 donor) 
DOI:10.5281/zenodo.1341943 
Minigene sequencing of T2 cells expressing a library of off targets (derived from A6 
and B7 binding motifs in Hausmann 1999) are co-cultured with A6, B7, DMF5 or 
1G4 expressing T cells (from a non-A2 donor) 
DOI:10.5281/zenodo.1342624 
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Results 
PresentER minigene design and validation 
The PresentER minigene was designed in two stages. First, we cloned into the MLP 
vector an endoplasmic reticulum (ER) signal sequence from the Mouse mammary 
tumor virus (MMTV). This sequence was modified at the 3’ end to include a 
removable cassette surrounded by SfiI restriction sites where DNA sequences 
encoding MHC-I ligands can be cloned (Figure 6). This vector is called the 
“PresentER Cassette” and includes an eGFP fluorescent marker and a Puromycin 
resistance gene. Subsequently, oligonucleotides encoding the HLA-A*02:01 ligands 
RMFPNAPYL (Human WT1:126-134), and ALYVDSLFFL (Human PRAME:300-309) 
were cloned into the SfiI-bracketed region of the PresentER vector. Tap deficient 
HLA-A*02:01+ T2 cells transduced with the PresentER-ALY and PresentER-RMF 
minigenes were stained with fluorescently labeled ESK1 and Pr20 to evaluate binding 
to MHC-I ligands expressed by the PresentER vector. Both ESK1 and Pr20 weakly 
bound T2 cells expressing their respective PresentER epitopes, but not irrelevant 
epitopes (Figure 7A-B). In order to demonstrate that PresentER encoded ligands 
could be presented on non-HLA-A*02:01 alleles, we cloned SIINFEKL (Chicken 
Ovalbumin:257-264) and MSIIFFLPL (mouse PEDF:271-279) into PresentER and 
showed that a TCR mimic antibody specific to H2-Kb/SIINFEKL (clone #25-D1.16) 
bound only to PresentER-SIINFEKL expressing Tap deficient RMA/S cells (Figure 
7C). 
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Figure 6 Schematic of PresentER cassette and minigene. (A) The PresentER 
vector is based on an MSCV retroviral vector. The peptide antigen minigene is driven 
by the MSCV LTR and encodes an endoplasmic reticulum (ER) targeting sequencing 
followed by the precise peptide to be expressed and a stop codon. The vector 
contains a puromycin resistance gene and eGFP driven by the PGK promoter. The 
ER sequence is the leader sequence from MMTV gp70 protein. A removable cassette 
(for easy cloning) is bounded by SfiI restriction sites. (B) The oligonucleotide 
sequence encoding the antigen is an inexpensive 75-78nt sequence and can be 
amplified, digested with SfiI and ligated into the backbone. (C) A schematic of the 
final PresentER minigene construct is shown.  
 
Figure 7: Binding of TCR mimic antibodies to human and mouse cell lines 
expressing PresentER antigens. T2 cells expressing PresentER-RMFPNAPYL 
(purple) and PresentER-ALYVDSLFFL (blue) are bound by fluorescently labeled (A) 
ESK1 and (B) Pr20, respectively. Irrelevant HLA-A*02:01 ligands serve as negative 
binding controls: Influenza M peptide 58-66 (green), Human WT1 239-247 (orange) 
and Human EW QLQNPSYDK (red). (C) A fluorescently labeled antibody to 
SIINFEKL/H-2Kb (clone 25-D1.16) binds to RMA-S cells expressing PresentER-
SIINFEKL, but not to the H-2Kb ligand PresentER-MSIIFFLPL. 
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T2 ESKm_T2_2_EW_001_014.fcs GFP Positive 1439 
T2 ESKm_T2_2_EW_002_015.fcs GFP Positive 1211 
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In order to verify that TCRs could bind to the presented peptides, we first obtained or 
purified two fluorescently labeled TCR multimers and verified that they could bind to 
their cognate targets. T2 cells expressing PresentER-NLVPMVATV (Cytomegalovirus 
pp65:495-503; HLA-A*02:01 ligand) were specifically, but weakly, bound by a high 
affinity TCR multimer directed to this epitope (Figure 8A). A tetramer made of A6 
TCR molecules linked to R-phycoerythrin (R-PE) showed specific binding to T2 cells 
expressing its target MHC-I ligand PresentER LLFGYPVYV (HTLV-1 Tax:11-19; HLA-
A*02:01 ligand) (Figure 8B). 
 
 
Figure 8 Binding of TCR multimers to T2 cells expressing PresentER antigens. 
(A) T2 cells expressing PresentER-NLVPMVATV 495-503 were bound by a 
fluorescently labeled STAR CMV pp65 directed TCR multimer. (B) A fluorescently 
labeled A6 TCR tetramer bound to its target ligand, HTLV-1 Tax 11-19 LLFGYPVYV.  
Irrelevant HLA-A*02:01 ligands serve as negative binding controls. 
 
In order to verify that presented peptides could be properly seen by T cells and thus 
that the system could be used for functional immunologic assays, we obtained two 
vectors encoding mammalian TCR that recognize two different cancer-associated 
antigens. The DMF5 TCR recognizes MART-1 27-35 (AAGIGILTV) while the 1G4 
NL
V
RM
F
AL
Y
0%
5%
10%
15%
20%
Pe
rc
en
t o
f G
FP
+ T
C
R
+  c
el
ls
AL
Y
RM
F
LL
F
0%
2%
4%
6%
8%
Pe
rc
en
t o
f A
6+
 c
el
ls
27 
 
TCR recognizes NY-ESO-1 157-165 (SLLMWITQC). In addition, we cloned the A6 
and B7 TCRs—which both recognize HTLV-1 Tax 11-19 (LLFGYPVYV)—out of the 
bacterial expression constructs (which lack intracellular domains) and into retroviral 
mammalian expression constructs. Human donor lymphocytes were transduced with 
the four TCRs and the ability of the T cells to activate and kill T2 PresentER minigene 
expressing target cells in co-culture was assayed by IFNg release ELISpot (Figure 9) 
and by killing of target cells (Figure 10A-B). T cells expressing the A6, 1G4 and 
DMF5 TCRs consistently activated at high levels when challenged with T2 cells 
expressing their cognate epitope. However, T cells expressing the B7 TCR 
consistently yielded low levels of activation. Activated splenocytes from OT-1 mice, 
which express a transgenic TCR specific to the SIINFEKL peptide (Ova 257-264) in 
the context of H-2Kb, were also able to kill co-cultured RMA/S cells expressing 
PresentER-SIINFEKL minigenes, but not irrelevant control minigenes (Figure 10C).  
 
 
 
Figure 9 T cell activation by PresentER expressing target cells. (A) ELISpot of 
genetically engineered T cells expressing the DMF5 TCR directed against the HLA-
A*02:01 ligand MART-1 27-35 (AAGIGILTV) challenged with T2 cells pulsed with 
peptide, expressing the PresentER MART-1 minigene or irrelevant NY-ESO-1 157-
165 (SLLMWITQC) peptide. (B) Genetically engineered T cells expressing the DMF5, 
1G4, A6 or B7 TCRs were challenged with peptide pulsed T2s and T2s expressing 
PresentER antigen minigenes. Quantification of spots is presented. 
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Figure 10 T cells kill co-cultured PresentER expressing target cells. 96-hour co-
culture killing assays in vitro where (A-B) A6, B7, 1G4 and DMF5 expressing T cells 
were incubated with T2 PresentER MART-1 (mCherry) cells mixed with (A) T2 
PresentER NY-ESO-1 minigene (GFP) cells or (B) Tax (GFP) cells and surviving 
target cells were quantified by flow cytometry. The fraction of target cells is 
normalized to the percentage in the wells without T cells. (C) RMA/S cells expressing 
SIINFEKL, MSIIFFLPL, SNFVFAGI or TAYRYHLL minigenes were mixed with 
activated splenocytes from OT-1 mice, C57BL6/N mice or no T cells. The fraction of 
target cells is normalized to the percentage in the wells without T cells. 
Based on the fact that PresentER drives antigen presentation in the absence of the 
TAP peptide transport, we hypothesized that the PresentER system would bypass 
proteasomal cleavage and processing in the generation of peptide-MHC. To test 
whether any peptide processing was occurring, we immunoprecipitated peptide-MHC 
complexes from T2 cells expressing PresentER-RMF or PresentER-ALY and 
identified bound peptides by mass spectrometry. RMFPNAPYL and ALYVDSLFFL 
were identified only in cells encoding those PresentER constructs (Figure 11A-B). 
Truncated versions of the RMF and ALY peptides were not found, nor were peptides 
derived from the ER signal sequence. In order to demonstrate that peptide 
presentation was dependent on the endoplasmic reticulum targeting sequence and 
not via another transport mechanism, we scrambled the ER signal sequence of the 
PresentER-RMF and PresentER-ALY constructs and stained them with ESK1 and 
Pr20. We found no binding to cells expressing scrambled constructs, indicating that 
the signal sequence is required for presentation of peptides in T2 cells (Figure 11C). 
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Figure 11 MHC-I ligands produced by PresentER minigenes are specific to the 
encoded peptide and depend on the ER signal sequence. MHC-I ligands were 
isolated from wild-type T2 cells or T2 cells expressing (A) PresentER-ALY or (B) 
PresentER-RMF. Peptides were identified by mass spectrometry and the intensity of 
ions corresponding to the ALY (A) or RMF (B) peptides in each sample are plotted. 
(C) ESK1 and Pr20 binding to T2 cells transduced with PresentER-RMF and 
PresentER-ALY is higher compared with binding to T2 cells expressing constructs 
with scrambled signal sequences. 
These experiments demonstrate that PresentER minigenes yield functional, mature 
MHC-I antigens which can be bound by TCR like molecules and recognized by T 
cells. Binding of fluorescently labeled TCR like molecules to cells expressing their 
target antigens using PresentER is significantly weaker than compared to binding to 
pulsed cells, which is expected given the significantly lower amount of antigen yielded 
by endogenous antigen presentation as compared to pulsing with micromolar 
quantities of soluble peptide. However, the levels of T cell activation between 
PresentER encoded antigens and pulsed peptides are similar. This is consistent with 
the fact that T cells require very few target pMHC in order to activate a productive T 
cell response53,54. Nevertheless, we proceeded to see if libraries of PresentER 
antigens could be used to screen for off targets of TCR like monoclonal antibodies. 
 
If the PresentER system is to dramatically increase throughput in the identification of 
cross-reactive targets of TCRs, it must be usable in a pooled screen, which is a form 
of high throughput genetic screening. In classical high throughput screening (HTS), 
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large numbers of chemical treatments or genetic variants are tested, one-by-one, and 
treatments/genes which yield a desired phenotype are identified. These screens are 
typically performed in 96 or 384 well plate format so that at each well in the plate it is 
known which treatment was used. Pooled screens enable less costly HTS of genetic 
variants because, instead of synthesizing individual genetic constructs and testing 
each gene in a separate well, all the genetic variants are cloned simultaneously in 
one reaction (typically into a retroviral vector) and a population of cells are transduced 
such that each cell expresses only one genetic variant on average. Attaining single-
variant-per-cell transduction is typically achieved by low multiplicities of infection 
(MOI) such that, on average, no cell receives more than one copy of a genetic 
construct and most cells receive no constructs. Cells which have not received a 
genetic construct are negatively selected. However, a major caveat of pooled screens 
is that the genetic constructs must be potent enough that a single genetic copy is 
capable of driving the phenotype55. In contrast to traditional HTS where cells may 
receive many copies of a gene, and thus single-copy competence is not as important, 
pooled screens fail unless a single copy of the genetic variant is sufficient for 
screening. To demonstrate that the PresentER system is single-copy competent, we 
transduced T2 cells with PresentER-RMF and PresentER-ALY with a 5-fold range of 
viral supernatant volume and achieved a 1-log difference in percentage of infected 
cells between the highest and lowest MOI transductions. Despite a 10-fold difference 
in the number of infected cells, the GFP positive cells in the population drive the 
same level of antigen presentation, thereby demonstrating that the system is single-
copy competent and can be used for pooled screens (Figure 12). 
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Figure 12 PresentER is a single-copy competent MHC-I antigen expression 
system. T2 cells were transduced with 5-fold serially diluted PresentER-RMF or 
PresentER-ALY viral supernatant in triplicate for each volume of virus. The percent of 
GFP positive, ESK1 positive cells after transduction is plotted as a function of 
percentage of cells infected (B and D). Across a 1-log range of low MOI infections, 
the same percentage of ESK1hi and Pr20hi cells are noted, indicating that a single 
copy of the minigene must be capable of driving antigen presentation.  
A PresentER screen of ESK1 reveals hundreds of cross-reactive pMHC 
 
During the initial characterization of both Pr20 and ESK1, low-throughput 
alanine/residue scanning identified several off-target HLA-A*02:01 ligand peptides. In 
combination with a crystal structure of ESK1 bound to RMFPNAPYL49 (Figure 13), 
we determined that ESK1 binding to RMFPNAPYL depended primarily on the R1 and 
P4 residues. In contrast, Pr20 bound mostly to the C-terminus of the ALYVDSLFFL 
peptide26. Therefore, we constructed a biased library (“PresentER Library #1”) of 
possible ESK1 and Pr20 cross-reactive targets by searching the human proteome in 
silico for 9-mer and 10-mer peptide sequences that might be off targets. For ESK1, 
we searched for peptides containing arginine in position 1 and proline in position 4. 
We performed a similar search for Pr20 cross-reactive targets using a 10-mer peptide 
motif based on prior biochemical data (Figure 14a). We located 1,157 and 24,539 
potential cross-reactive peptides of ESK1 and Pr20, respectively, with NetMHCPan56 
predicted HLA-A*02:01 affinity of less than 500nM. We synthesized a pool of 12,472 
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oligonucleotides that together encoded all of the ESK1 cross reactive peptides and 
half of the Pr20 cross-reactive targets plus the one amino acid mutants of RMF and 
ALY (termed “CR-ESK1” and “CR-Pr20”, respectively), as well as positive/negative 
controls (Figure 14b). The oligonucleotide library was cloned into the PresentER 
vector following a scaled-up protocol of the cloning of individual minigenes. To ensure 
that exponential amplification during PCR had no compromised the distribution of 
minigenes in the population, the cloned library was sequenced by Illumina HiSeq. All 
synthesized minigenes were found in the plasmid pool and no extreme outliers were 
noted (Figure 15).  
 
 
Figure 13 Crystal structure of ESK1 in complex with HLA-A*02:01/RMFPNAPYL.   
RMFPNAPYL binds HLA-A*02:01 with Met2, Phe3, Pro7, and Leu9 facing the HLA 
receptor and Arg1, Pro4, Asn5, and Tyr8 facing ESK1. The heavy and light chains of 
ESK1 are in orange and cyan. Arg1, Pro4 and Asn5 are within van der Waals 
distance to ESK1. Figure and caption adapted from Ataie et al 201849, 
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Figure 14 Design of PresentER library #1 and ESK1 screen.  
(A) Design of sequence constraints on the target peptide library based on prior 
biochemical data. The human exome was mined for peptides matching the specified 
ESK1 and Pr20 consensus motifs. Asterisks indicate any amino acid is allowed. Red 
characters indicate prohibited amino acids at that position and black characters indicate 
allowed amino acids at that position. (B) The constructed library included 13 control 
peptides, 1,337 CR-ESK1 peptides and 11,083 CR-Pr20 peptides. 
 
1 2 3 4 5 6 7 8 9 10
ESK1 Target R M F P N A P Y L -
ESK1 Library R * * P * * * * * -
Pr20 Target A L Y V D S L F F L
Pr20 Library * * * DE KH
R
K
H
R
K
H
R
FW
YV
LI
FW
YV
LI
L
V
I
# Constructs (%)
Controls 13 (0.1%)
CR-ESK1
RMFPNAPYL: all 1 AA mismatch 180 (1.45%)
ESK1 genomic off-targets 1,157 (9.3%)
CR-Pr20
ALYVDSLFFL: all 1 AA mismatch 190 (1.5%)
Pr20 genomic off-targets 10,893 of 24,539 (87.6%)
Total 12,433
A
B
34 
 
 
Figure 15 PresentER Library #1 minigene representation analysis.  
Minigene sequences from PresentER Library #1 were amplified and sequenced by 
Illumina HiSeq. All synthesized minigenes were located in the cloned library and, while 
there were some highly abundant outliers, no outlier was present at more than a log 
higher than the median abundance in the population. 
 
The flow-based screen assaying for cross-reactivity was performed as follows: 
HEK293T Phoenix Amphoteric cells were transfected with library plasmid. After 24 
hours, viral supernatant was harvested every 12 hours, concentrated using Retro-X-
Concentrator, and frozen in aliquots. The library viral supernatant functional titer was 
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determined under the same transduction conditions as used for transduction of T2 
cells in order to determine the volume that yielded 1/3 maximal MOI. T2 cells were 
transduced at 1/3 MOI and transductants were selected with puromycin. Library 
representation was kept at >1,000x at all stages. Finally, transduced T2 cells were 
stained with ESK1 or Pr20 and sorted by fluorescence-activated cell sorting (FACS) 
into two populations: high binders and low binders (i.e. ESK1hi, ESK1low, Pr20hi, 
Pr20low. Genomic DNA from sorted cells was extracted, minigenes were amplified by 
PCR and sequenced by Illumina HiSeq. Sequences were aligned to the library of 
minigenes and the number of reads mapping to each minigene was quantified. A 
schematic of the screen is presented in Figure 16. 
 
 
Figure 16 Schematic of the flow-based screen. T2s are transduced at low MOI 
(<0.3) with retrovirus encoding a pool of PresentER minigenes. Transduced cells are 
selected by puromycin and then cultured until sufficient cells are obtained. Cells are 
stained with the TCR mimic antibody and fluorescent activated cell sorting is used to 
sort binding and non-binding populations of cells. Genomic DNA is extracted from 
sorted cells and sequenced with Illumina sequencing. 
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The abundance of each minigene in the unsorted samples was well correlated (r = 
0.93), indicating that sample handling and the days between sorts did not affect the 
library representation (Figure 17A). An ESK1 binding enrichment score was 
calculated for each minigene, taking into account the abundance of each minigene in 
the ESK1hi, ESK1low and unsorted samples:  
 
(frequency in ESK1hi) / (frequency in ESK1low) / (frequency in unsorted). 
 
 Minigenes encoding previously known ESK1 ligands had higher enrichment scores 
than those encoding non-ligands (p=0.032), suggesting that the flow-based screen 
was able to separate ESK1 binders from non-binders (Figure 18) 
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Figure 17 Minigene abundance in unsorted samples is highly correlated. The 
abundance of each minigene in the two unsorted samples taken before ESK1 sorting 
(A). The abundance of each minigene in the three unsorted samples taken prior to 
Pr20 sorting: 1 vs 2 (B), 1 vs 3 (C) and 2 vs 3 (D). Correlation coefficients are 
reported. 
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Figure 18 Enrichment of known ESK1 binders in screen. The enrichment scores 
of control peptides known to be either ESK1 binders or know ESK1 non-binders are 
compared. Known ESK1 binders were enriched in the pull down (p=0.032). 
A scatter plot comparing ESK1 enrichment and NetMHCPan predicted HLA A*02:01 
binding affinity of all 12,434 minigenes in the library is presented in Figure 19. 
Surprisingly, several of the most enriched peptides that emerged in the ESK1 screen 
were CR-Pr20 peptides (marked as squares). Although the target of ESK1 is a 9-mer, 
several of the CR-Pr20 10-mers that were enriched for ESK1 binding bore sequence 
similarity to RMFPNAPYL, the target of ESK1, such as RVIMPCNWWV and 
RMFSGVGVYL. To validate the ESK1 hits, we synthesized soluble peptide for a 
subset of screen hits and assayed them for binding to ESK1 by pulsing T2 cells. Of 
the 27 peptides tested, 22 (81%) showed increased binding to ESK1, including 
several CR-Pr20 peptides which did not even contain a proline in position 4 (Figure 
20). Of great importance is that these unusual ESK1 ligands could not have been 
predicted from either the crystal structure of ESK1 or the alanine scanning data. 
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Figure 19 Scatterplot of the ESK1 library screen. Each point is a unique peptide 
minigene with the x-axis indicating enrichment for ESK1 binding (with 1 set as no 
enrichment) and y-axis indicating the peptide’s predicted affinity (ic50 nM) to HLA-
A*02:01. Lower ic50 indicates higher affinity. Marked negative control ESK1 non-
binders are marked as blue triangles. Previously known ESK1 ligands are plotted as 
light orange triangles. CR-ESK1 are plotted as circles and CR-Pr20 as squares. 
Peptides which were validated by an orthogonal method as bonafide ESK1 ligands 
are colored red. Peptides which were tested and found not to be ESK1 ligands are 
colored in dark blue. 
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Figure 20 Validation of ESK1 hits by peptide pulsing. 27 peptides that were highly 
enriched for ESK1 binding and had high predicted affinity to HLA-A*02:01 were 
synthesized at microgram scale, pulsed onto T2 cells at 50µg/ml (~500µM) and 
stained with a fluorescently labeled ESK1. Previously identified cross-reactive targets 
were included as positive controls. The median fluorescence intensity (MFI) of ESK1 
binding is plotted, normalized to RMFPNAPYL, set at 100 units. 
 
Recently, large databases of HLA-A*02:01 peptide ligands isolated from tumors and 
normal tissue have become available4,41,42,57. Within these databases (including 
personal correspondence with Department of Immunology members at Tübingen) we 
found 48 nine-mer peptides with Arg1 and Pro4. Forty-five had been included in the 
library of CR-ESK1 peptides identified in silico from the human proteome. We 
synthesized 27 of these and found that 17 (63%) bound to ESK1 when pulsed on T2 
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cells. The median ESK1 enrichment in the flow-based screen of these 17 peptides 
was 1.8 whereas the median enrichment of the non-binders was 0.86 (Figure 21), 
indicating that these ESK1 ligands were enriched in the screen, even if they were not 
among the top hits.  
 
 
Figure 21 ESK1 screen enrichment scores of bonafide HLA-A*02:01 ligands 
also found in the set of CR-ESK1 peptides.  An additional 27 CR-ESK1 peptides 
were identified as ligands of HLA-A*02:01 by immunoprecipitation of HLA followed by 
mass spectrometry to identify peptides. These peptides were synthesized and tested 
for binding to ESK1. The flow-based ESK1 enrichment scores of the 17 ESK1 binders 
and 10 non-binders are plotted. p=0.00834 by Welch two sample t-test. 
 
Two WT1-negative58 cell lines with HLA-A*02:01 ligandomes that have been 
characterized by immunopeptidomics were found to present ESK1 off-targets 
discovered in the PresentER screen (TPC-1 cell line: RLPPPFPGL, RVMPSSFFL, 
RLGPVPPGL, JY cell line: KLYNPENIYL, RLVPFLVEL). RMFPNAPYL was not found 
among the MHC-I ligands immunoprecipitated from these lines. We tested ESK1 
binding in these lines and found that JY cells bound ESK1 at high levels while TPC-1 
was marginally positive for ESK1 binding (Figure 22).  
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Figure 22 ESK1 binds to two cell lines presenting ESK1 cross-reactive ligands. 
(A) Representative ESK1 and isotype staining of the JY cell line. (B) Quantification of 
ESK1 and isotype staining of the JY and TPC1 cell lines. 
 
A PresentER screen of Pr20 reveals dozens of cross-reactive pMHC 
 
A screen of Pr20 cross-reactive ligands was performed in the same manner as 
described above. The abundance of each minigene in the unsorted samples was 
highly correlated (r=0.90-0.94) (Figure 17 B-D). Unlike in the ESK1 screen, positive 
control peptides that were known Pr20 ligands were not enriched relative to the 
negative controls (p=0.71) (Figure 23). However, twenty peptides were enriched for 
Pr20 binding at least 5-fold and had predicted ic50s of less than 100nM, suggesting 
they might be Pr20 off-targets (Figure 24). 45 peptides were synthesized, including 
the 20 enriched in the Pr20 off-target screen and several additional bonafide HLA-
A*02:01 ligands identified by mass spectrometry that matched the Pr20 ligand 
consensus sequence. Of these, 28 (62%) were found to be Pr20 ligands when the 
peptides were pulsed onto T2 cells, including 3 known HLA-A*02:01 ligands. The 28 
validated peptides were more enriched for Pr20 binding in the screen than the 17 
non-validated peptides (Figure 25). 
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Figure 23 Pr20 screen enrichment scores of positive and negative control Pr20 
ligands. The flow screen enrichment scores of control peptides known to be Pr20 
binders or non-binders before screening shows no enrichment of positive control 
peptides compared to negative control peptides. P-value = 0.71 by Welch two sample 
t-test. 
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Figure 24 Minigenes enriched in Pr20 screening validate as Pr20 ligands. The 
netMHCPan predicted HLA-A*02:01 affinity in ic50 (nM) and Pr20 enrichment score 
of all screened peptides. Each point is a unique peptide minigene. The x-axis 
indicates enrichment for Pr20 binding (with 1 set as no enrichment) and y-axis 
indicates the peptide’s predicted affinity to HLA-A*02:01 (ic50 nM). Lower ic50 
indicates higher affinity. Previously known Pr20 ligands are plotted as light orange 
triangles. CR-ESK1 are plotted as circles and CR-Pr20 as squares. Peptides which 
were validated by an orthogonal method as Pr20 ligands are colored red. Peptides 
which were tested and found not to be ESK1 ligands are colored in dark blue. 
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Figure 25 Pr20 screen enrichment scores of peptides that were validated as 
Pr20 ligands by peptide pulsing. The flow cytometry screen enrichment scores of 
peptides that were tested for Pr20 binding. Peptides were chosen because of their 
enrichment in the Pr20 screen or because the peptides were identified in a database 
of HLA-A*02:01 ligands. 
 
The ESK1 and Pr20 off targets discovered by screening bind more strongly to ESK1 
and Pr20 than the intended WT1 and PRAME peptide targets 
 
Examining only the CR-ESK1 subset of peptides, we noticed that the peptides most 
enriched for ESK1 binding were also predicted to have the highest affinity for HLA-
A*02:01 (Figure 26). The peptides that are ≥5-fold enriched for ESK1 binding have a 
median affinity to HLA-A*02:01 of 31nM, compared to 95nM for the library as a whole 
and 102nM for ≥5-fold depleted peptides (Figure 27A). We found the same result in 
the Pr20 screen: the most enriched Pr20 ligands also had the highest affinity to MHC-
I (Figure 27B). We cloned minigenes for four of the most enriched CR-ESK1 
(RLFPLAWTV 31.8x; KLMGAISFFI 41.9x) and CR-Pr20 (WLLGDSSFFL 6.5x; 
LLIQEGPFFV 6.6x) peptides and tested them for binding to ESK1 and Pr20. 
Compared to the original ESK1 and Pr20 targets—RMFPNAPYL and 
ALYVDSLFFL— cells expressing these four off-targets bound ESK1 and Pr20 at 
much higher levels (Figure 28). 
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Figure 26 ESK1 screen enrichment scores for CR-ESK1 peptides only. 
Scatterplot of the ESK1 library screen with only CR-ESK1 peptides (and controls) 
plotted. Each point is a unique peptide minigene with the x-axis indicating minigene 
enrichment for ESK1 binding (with 1 set as no enrichment) and y-axis indicating the 
peptide’s predicted ic50 (in nM) to HLA-A*02:01. Lower ic50 indicates higher affinity. 
Marked control peptides and known ESK1 target peptides are plotted as triangles and 
CR-ESK1 peptides as circles. Peptides that were validated by an orthogonal method 
as bonafide ESK1 ligands are colored red. Peptides which were tested and found not 
to be ESK1 ligands are colored in dark blue. 
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Figure 27 Peptides enriched in TCRm screening are predicted to be high affinity 
MHC-I ligands. The netMHCPan predicted HLA-A*02:01 affinity in ic50 (nM) of all 
screened peptides compared to peptides which were ≥5-fold depleted in the ESK 
screen and peptides that were ≥5-fold enriched for ESK1 binding. (B) The 
netMHCPan predicted HLA-A*02:01 affinity in ic50 (nM) of all screened peptides 
compared to peptides that were ≥5-fold, ≥3-fold or ≥2-fold enriched in the Pr20 screen 
and peptides that were ≤3 or ≤2-fold depleted for Pr20 binding. 
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Figure 28 ESK1 and Pr20 staining of outstanding ESK1 and Pr20 ligands.  
Four minigenes encoding peptides that were highly enriched in the screen of ESK1 and 
Pr20 off targets were cloned. T2 cells transduced with the peptide minigenes were 
stained with fluorescently labeled ESK1 and Pr20 and showed that the minigene 
encoded antigens were exceptional binders to ESK1 and Pr20. In fact, these antigens 
bind better to ESK1 and Pr20 than the targets against which these TCR mimic 
antibodies were designed.  
 
PresentER can be used to discover the targets of T cell receptors 
 
In the previous sections, we have described how pooled screening with the 
PresentER system may be used to identify both theoretical and, in some cases, 
actually presented MHC-I peptide off-targets of TCR mimic antibodies. Next, we 
turned our attention to T cells and asked if we could identify the targets and off-
targets of T cells. Human T-lymphotropic virus 1 (HTLV-1) associated 
myelopathy/tropical spastic paraparesis (HAM/TSP) is an immune-mediated disease 
primarily of the spinal cord that occurs in a small fraction of individuals infected with 
the HTLV-1. Patients with HAM/TSP can develop antibodies that recognize both the 
HTLV-1 Tax protein and the C-terminus of human heterogeneous nuclear 
ribonucleoprotein A159, which is thought to possibly underlie the pathogenesis of the 
ESK1
RMFPNAPYL
RLFPLAWTV
KLMGAISFFI
WLLGDSSFFL
LLIQEGPFFV
ALYVDSLFFL
Pr20
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disease. However, patients also have circulating T cells that recognize an antigenic 
N-terminal epitope of the virus: Tax 11-19 LLFGYPVYV presented on HLA-A*02:01. It 
is unknown if there is cross-reactivity between the HTLV-1 Tax-directed TCRs and 
wild-type peptides presented on HLA-A*02:01 that might be associated with the 
pathogenesis of HTLV-1. The A6 and B7 TCRs were both derived from a HAM/TSP 
patient and both recognize the Tax 11-19 peptide, albeit with two different binding 
modes60. These two TCR clones have been well characterized over the past two 
decades (the A6 TCR is the first human TCR structure to be solved in complex with 
peptide and MHC-I7) and dozens of off-targets that differ from the original peptide by 
only a single amino acid are known51,60,61. We cloned the A6 (also known as “2G4”) 
and B7 TCRs into a mammalian expression vector and transduced donor T cells with 
these constructs or with the irrelevant 1G4 and DMF5 TCRs. The transduced T cells 
were functional and could recognize PresentER encoded target cells as assessed by 
ELISpot (Figure 9) and co-culture killing assays (Figure 10).  
 
We constructed a library of possible off-targets of A6 and B7 by scoring all 9-mer 
peptides with NetMHCPan predicted HLA-A*02:01 ic50 of <500nM in the human 
proteome for likelihood of being targets of A6 and B7, based on preexisting peptide-
specific cytotoxicity data (Figure 29A-C)60. The 5,000 peptides with top A6 or B7 
binding scores were selected to make a PresentER minigene library (Figure 29D). All 
single amino acid substitutions to Tax 11-19 LLFGYPVYV were included in the 
library, as well as several control peptides. The library was constructed as before, 
sequence validated by Illumina sequencing and is referred to as the “A6B7 library” 
(Figure 29E). As before, T2 cells were spinoculated at 1/3 MOI with the A6B7 library 
and transductants were selected with puromycin. 
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Figure 29 Design of the A6B7 off target PresentER library. The cytotoxicity scores 
reported in Hausmann et al (1999) for each amino acid substitution to Tax 11-19 
LLFGYPVYV were used to construct a sequence logo indicating the consensus (A) 
A6 and (B) B7 peptide target. (C) All human 9-mer peptides predicted to bind to HLA-
A*02:01 (ic50<500nM) were ranked using the A6 (x-axis) and B7 (y-axis) motifs and 
plotted. (D) The 5,000 peptides selected for the A6B7 off-target library are the top 
predicted A6 and B7 peptides. (E) Representative sequencing of the library to confirm 
normal distribution of the minigenes and no outliers. 
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A6, 1G4 and DMF5 expressing T cells were co-cultured with T2 cells expressing the 
A6B7 library for 96 hours in 96 well U-bottom plates. All cells were pooled and re-
dispersed across the 96 well plates daily to prevent well-specific outgrowth or 
depletion. After 96 hours, cells were harvested, genomic DNA was extracted and 
minigenes sequenced. When we compared T2s that had not been co-cultured with T 
cells (in triplicate) to T2s that had been cultured with 1G4 or DMF5, we saw excellent 
correspondence between the samples and no minigenes that were robustly depleted 
(Figure 30A-B). By contrast, over 80 minigenes were depleted at least 2-fold in the 
library co-cultured with A6 T cells (Figure 30C). Strikingly, all of these depleted 
peptides were single-residue substitutions of the original Tax 11-19 peptide. For 
instance, the most strongly depleted peptides were L1S (46x), Y9C (35x), L2C (30x). 
In general, there was excellent overlap between the peptides discovered by 
PresentER and the peptides that fit the motif derived from Hausmann as A6 ligands60 
(Figure 31). 
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Figure 30 Abundance of minigenes in A6B7 library after co-culture with DMF5, 
1G4 or A6 TCRs. T cells expressing (A) DMF5, (B) 1G4 or (C) A6 were co-cultured 
with the PresentER A6B7 library for 96 hours and all cells were harvested and 
minigenes sequenced. Each point is a minigene.  Circles are peptides from the 
human proteome, squares are single amino acid substitutions of the Tax 11-19 
peptide and triangles are control peptides. The x-axis indicates the abundance of 
each minigene in the “no T cells” group while the y-axis indicates the abundance of 
each minigene after depletion with one of the recombinant T cells. 
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Figure 31 Abundance of minigenes in A6B7 library after co-culture with A6 
library and shaded by A6 score. T cells expressing A6 were co-cultured with the 
PresentER A6B7 library for 96 hours and all cells were harvested and minigenes 
sequenced. Each point is a minigene.  Circles are peptides from the human 
proteome, squares are single amino acid substitutions of the Tax 11-19 peptide and 
triangles are control peptides. All minigenes are shaded according to their similarity to 
the A6 ligands described by Hausmann60 
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The A6B7 library depletion was repeated with freshly transduced PBMCs from a 
different donor expressing A6, B7, 1G4 and DMF5 TCRs. As in the first co-culture 
depletion experiment, 1G4 and DMF5 T cells did not deplete any minigenes in the 
library (Figure 32A-B), but both A6 and B7 T cells depleted some single amino acid 
variants of the Tax peptide (Figure 32C-D). There was striking consistency between 
the peptides depleted by T cells expressing the A6 TCR in the first and second 
experiments (Figure 32E), suggesting that inter-experimental variability of minigene 
depletion was low. With the inclusion of the B7 TCR in the depletion study, we were 
able to compare the targets of A6 and B7. 70 and 42 peptides were >2-fold depleted 
by the A6 and B7 TCRs, respectively, with 36 overlapping peptides. These results are 
consistent with the more stringent binding requirements of the B7 TCR . Indeed, by 
color-coding the minigenes according to A6 and B7 binding motifs derived from 
Hausmann 1999, we can clearly see that the majority of A6 depleted peptides fit the 
A6 binding motif (Figure 32E-F). Similarly, the peptides depleted by both A6 and B7 
form a distinct group with the highest possible B7 scores (Figure 32E-G). Some 
peptides with high A6 and B7 scores are not depleted by A6 or B7 T cells, indicating 
that while they may be ligands when pulsed as soluble peptide onto cells, they are 
likely not ligands when expressed endogenously. 
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Figure 32 Abundance of minigenes in A6B7 library after co-culture with DMF5, 
1G4, A6 or B7 TCRs. T cells expressing (A) DMF5, (B) 1G4, (C) A6 or (D) B7 were 
co-cultured with the PresentER A6B7 library for 96 hours and all cells were harvested 
and minigenes sequenced. Each point is a minigene. Triangles are peptides from the 
human proteome, squares are single amino acid substitutions of the Tax 11-19 
peptide and circles are control peptides. The x-axis indicates the abundance of each 
minigene in the “no T cells” group while the y-axis indicates the abundance of each 
minigene after depletion with one of the recombinant T cells. (E) Comparison of 
minigenes depleted (relative to the no T cells sample) in the first  A6 co-culture 
experiment and the second A6 co-culture experiment shows excellent 
correspondence, indicating that the library depletion is robust to inter-experimental 
variability. (F-G) Comparison of the A6 and B7 depletion of the off-by-one peptides 
shows that most peptides recognized by B7 are also recognized by A6. However, 
there is a subset of peptides that is only recognized by A6. The peptides are colored 
by A6 score (F) or B7 score (G) to show that both scoring systems are predictive of 
which peptides are recognized by A6 and B7. 
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Discussion 
The ability to rapidly identify the targets of T cells and, by extension, TCR like 
molecules, is a major goal in the field of immunology. Here, we have described a 
method we term “PresentER” to identify the targets of TCR like therapeutic molecules 
as well as T cells. The PresentER system generates low levels of antigen 
presentation relative to peptide pulsing, but sufficient antigen is generated to be 
detected by fluorescently labeled TCR mimic antibodies and antigen-specific T cells. 
We screened two TCR mimic antibodies and two engineered T cells against libraries 
of exomic peptides and found, for the antibodies, hundreds of cross-reactive targets. 
Although we did not find any human exome-derived peptides that were cross-reactive 
with T cells expressing the A6 or B7 TCRs, we did re-confirm that these TCRs bind 
and kill cells expressing 70-80 different single-amino acid substituents of the Tax 
peptide. 
 
Previously known ligands of ESK1, Pr20 and A6/B7 were not all identified by flow-
based or depletion-based screening of PresentER minigenes. In each case, these 
ligands were originally identified by pulsing T2 cells or HLA-A*02:01 PBMCs with 
saturating quantities of each peptide. We speculate that while some of these peptides 
may be biochemical ligands of the TCR/TCRm, they may not be well presented when 
expressed genetically, either because of inefficient loading onto MHC-I or negative 
selection during peptide editing, e.g. by TAPBPR12. Indeed, the skew we observed in 
both ESK1 and Pr20-enriched minigenes towards high-affinity HLA-A*02:01 ligands 
suggests that genetic expression of peptides selects for presentation of ligands with 
the highest affinities for HLA-A*02:01. This is be an unexpected feature of 
PresentER, as affinity to MHC-I is the most important factor in determining if a peptide 
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is presented on MHC-I (although high expression levels may overcome low affinity11). 
This suggests that methods for generating large number of pMHC in vitro by 
covalently attaching a peptide to the MHC may lead to artificial presentation of 
peptides that would never be presented endogenously. Additional study of the 
difference between genetic expression of MHC-I ligands and peptide pulsing should 
be pursued to help investigators decide which cross-reactive peptides are likely to be 
endogenous MHC-I ligands and thus pose a risk to patients in a clinical setting. 
 
Although we did not identify any human peptide ligands of the A6 TCR, we did 
demonstrate the PresentER can be used to identify the targets of T cells in a pooled 
co-culture screen. We were able to re-confirm 70-80 peptides as targets of the A6 
TCR. Interestingly, cells expressing PresentER-MLWGYLQYV (Yeast Tel1p) and 
PresentER-LGYGFVNYI (Human HuD / ELAVL4) were not depleted in the A6B7 
library when co-cultured with A6 T cells, nor were they depleted in individual co-
culture assays. Moreover, several other substituted peptides that had been reported 
by Hausmann to bind A6 did not deplete in the library assay. For instance, the Tel1p 
and HuD/ELAVL4 peptides were identified by Hausmann as cross-reactive targets of 
A6 by peptide pulsing. However, biochemical studies of soluble A6 binding to Tel1p 
and HuD have shown the A6/peptide/HLA-A2 complex to be weakly stable and less 
favorable than the interaction between Tax/HLA-A2/A650,62. Thus, we hypothesize that 
the discrepancies between the results of our screen and the findings of Hausmann 
reflect the much stricter constraints imposed on peptide loading and more physiologic 
levels of antigen presentation by endogenous peptide presentation in contrast to 
exogenous peptide pulsing  
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Preclinical evaluation methods for novel therapeutic agents directed towards peptide-
MHC have been insufficient to prevent harmful off-tumor off-target toxicity. Indeed, 
even recent reports of engineered anti-cancer TCRs show preclinical evaluation of 
only hundreds of off-target peptides, most of which are merely single amino acid 
substitutions63,64. In PresentER, we have developed a mammalian screening 
approach to prospectively identify thousands of cross-reactive MHC-I ligands. While 
PresentER may not detect all naturally expressed cross-reactive epitopes and may 
detect epitopes that are never presented in an endogenous setting, the system can 
help to identify potential cells and tissues at risk for closer clinical surveillance. The 
PresentER system is easy to scale-up and a sufficiently well-funded company could 
survey the entire human proteome for cross-reactive ligands. Large libraries of 
PresentER encoded ligands spanning the whole human proteome could be used to 
discover the off-targets of TCR agents before any patients is exposed to toxicity. 
Using the relatively non-conservative 500nM cut-off for HLA-A*02:01 binding, there 
are ~750,000 possible HLA-A*02:01 peptides that can be found in the human 
proteome (Figure 5). 75 libraries organized in conveniently assayable sets of 10,000 
peptides could be synthesized for less than $50,000 and an engineered/cloned TCR 
could be tested against this library for $100,000-$200,000 of reagent and sequencing 
costs. This cost is a fraction of the billions of dollars typically spent during drug 
development65 and would go far to ensure that such drugs are safe to give to the first 
patient on a phase I clinical trial. 
 
We have shown that PresentER can be used for biochemical evaluation of potentially 
therapeutic TCR based agents. PresentER can also be used as an immune 
presentation platform in vitro and in vivo; thus, this work can be expanded to 
recapitulate the MHC restricted antigenic diversity of human cancer. Libraries of 
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MHC-I ligands could be used to ask how tumor neoantigen heterogeneity affects 
progression and treatment of tumors in immunocompetent animals, and address 
areas such as neoantigen immunogenicity and clonality, cancer vaccination and 
immunoediting. 
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Chapter II: Rejection of immunogenic tumor clones is limited by clonal fraction 
Introduction 
Human cancers bear uniquely distinguishable features on the surface of their cells in 
the form of neoantigens, comprised of peptides derived from mutated, foreign or 
oncofetal proteins that are presented in complex with Major histocompatibility 
complex I (MHC-I) molecules. These short, 8-11 amino acid fragments can 
specifically mark cancer cells and activate potent immune responses that, when 
harnessed, can lead to effective anti-cancer therapy19,21,66. Karl Hellström first 
described the coexistence of tumor-specific lymphocytes together with cancer cells in 
human solid tumors as a paradox 50 years ago67. In mice, an analogously enigmatic 
observation has been made that sporadic tumors occurring in aged or carcinogen-
treated mice induce strong T cell responses when transferred into new hosts, 
preventing engraftment68-70. Although it is known that tumor-specific T cells can lead 
to tumor rejection in a new host or when used as a cancer therapy, it is not 
understood how and to what extent immune surveillance is evaded during early 
tumorigenesis in the original host that developed an immunogenic tumor. The 
increased rate of tumor formation in immunocompromised individuals has led to the 
hypothesis that the immune system can and does eliminate some tumors, particularly 
virally induced tumors, before they become clinically apparent71. We hypothesize that 
if the immune system can eliminate some early tumors, but not others, perhaps it is 
because some antigens are more potent at inducing effective T cell responses during 
early tumorigenesis. Identification and characterization of neoantigens that can 
induce an effective immune response and clear cancer cells is critical to 
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understanding why and how immunogenic tumors develop in immunocompetent 
hosts. 
Some immunogenic peptides have been discovered in animal studies by injection of 
thousands or millions of tumor cells bearing neoantigens into animals and observing 
tumor rejection. However, the robust immune activation and tumor rejection in these 
cases is not analogous to the events of early tumorigenesis in humans, when the 
number of transformed cells is miniscule. Thus, even though some tumors are 
immunogenic, it is not clear why the host cannot eliminate them when the tumors first 
arise. If the biochemical features of neoantigens that lead to effective T cell 
responses were known, it might be possible to identify which tumors bear 
immunogenic antigens. Some reports have linked peptide immunogenicity to the 
characteristics of some residues at certain positions along the MHC-I ligand72, while 
others have focused on the difference between the affinity of a wild-type ligand and a 
mutated ligand73. However, the absence of a large, unbiased data set of known 
immunogenic and non-immunogenic peptides has stymied the validation of these 
approaches. Indeed, most known immunogenic antigens are derived from viral 
proteins and few mutationally-derived neoantigens are confirmed as bonafide 
immunogenic peptides in mice or humans.  Here, we have used the PresentER 
method to express libraries of precisely defined MHC-I ligands in mammalian tumor 
cells and have used this method to ask questions about MHC peptide immunogenicity 
in immunocompetent animals during early tumorigenesis. 
Using libraries of PresentER encoded MHC-I ligands, we tracked the dynamic growth 
and depletion of thousands of tumor subclones in vivo and noted a striking failure of 
cancer immunosurveillance that is potentially analogous to the failure of immune 
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surveillance in humans during early tumorigenesis. We demonstrate for the first time 
that the ability of the naive immune system to surveille a nascent tumor and reject 
immunogenic subclones is limited by the fraction of cells expressing each unique 
antigen. Furthermore, we show that these rejection thresholds vary among antigens. 
Our data are consistent with the observation in humans that patients whose tumors 
have high numbers of subclones—and thus more subclonal neoantigens—have 
increased levels of relapse and worse survival than patients with more homogenous 
tumors74-76. Thus, our data provide an antigen-specific rationale for the impact that 
tumor heterogeneity has on survival of human patients. According to our findings, 
antigen-specific immune effects are limited during early tumorigenesis, which has 
implications for the emergence and outgrowth of immunogenic tumors. 
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Materials and Methods 
 
Animal Studies 
6-8 week old C57BL6/N mice were purchased from Envigo or Taconic Biosciences. 6-
8 week old B6.SJL-Ptprca/BoyAiTac (known as CD45.1 mice) and B6.129S6-
Rag2tm1Fwa N12 Mice (known as RAG2 KO) were purchased from Taconic 
Biosciences. Mice were shaved before subcutaneous engraftment of indicated 
number of RMA/S cells in 100 uL PBS. Tumor volumes were calculated using caliper 
measurements and the standard modified ellipsoid formula: tumor volume = 
(LxW2)x0.52 every 2-3 days. Animals were euthanized when tumor volume exceeded 
2000 mm3 or if ulceration was noted. Vaccination of animals was performed by 
subcutaneous injection of 10x106 irradiated (20 Gy) MCA205-ΔTAP2 cells expressing 
libraries of minigenes. 
 
Flow Cytometry 
For cell surface staining, cells were incubated with appropriate fluorophore-
conjugated mAbs for 30 minutes on ice and washed twice before resuspension in the 
viability dye DAPI at 1 μg/mL. Flow cytometry data were collected on a LSRfortessa 
(BD) or an Accuri C6 (BD) and analyzed with FlowJo V10 software. The antibodies 
used in this study were anti-H-2Kb-APC clone AF6-88.5 (Biolegend 116517), anti-
SIINFEKL/H2kb-APC clone 25-D1.16 (Biolegend 141605), anti-CD45.2-APC clone 
104 (eBioscience 17-0454-81), anti-CD8a-FITC clone Ly-2 (BD Pharmingen 553030), 
anti-CD3-PerCP clone 145-2C11 (BD Pharmingen 553067). The following 
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fluorescently labeled H-2Kb tetramers were obtained through the NIH Tetramer Core 
Facility: SIINFEKL, SIYRYYGL, MSIIFFLPL, SNFVFAGI and VTFVFAGL. 
Generation of MCA205-ΔTAP2 
A guide RNA sequence targeting murine TAP2 (ATGGGGCTGTTGCGCTGAGC) was 
cloned into the LentiCRISPRv277 plasmid (Addgene plasmid 52961), a gift from Feng 
Zhang (Broad Institute, Cambridge, Massachusetts, USA). MCA205 fibrosarcoma 
cells were transiently transfected using Lipofectamine 2000 (Thermo Fisher Scientific 
11668027) following standard manufacturer’s protocols. 24 hours later, successful 
transfectants were selected using 5 ug/mL Puromycin for 3 days before expansion 
and single-cell subculture. Genetic ablation of TAP2 was verified by next generation 
sequencing of the TAP2 loci confirming a frameshift deletion in both alleles, and RT-
PCR analysis with the following primers (TAP2 For: CACAGCCACCACAAGGAAGA, 
TAP2 Rev: CAGTTCCTGTCCAGTCGCAT, mGAPDH For: 
TGATGGGTGTGAACCACGAG, mGAPDH Rev: TCTTGCTCAGTGTCCTTGCT). 
Reduced cell-surface H-2Kb expression was also verified by flow cytometry. 
Determination of antigen-specific immunogenicity thresholds 
RMA/S cells expressing PresentER antigen #1 (eGFP) were mixed with RMA/S cells 
expressing PresentER antigen #2 (mCherry) at defined ratios (e.g. 1:10, 1:100, 
1:1000, etc) and validated by flow cytometry immediately before injection into CD45.1 
mice. After 17 days, tumors were harvested, cut into small pieces and disaggregated 
by incubation at 37ºC with Liberase (TL (Sigma-Aldrich 5401020001), DNAse I 
(Worthington Biochemical LS002139) and ACK lysis buffer (Thermo Fisher Scientific 
A1049201). Single cell suspensions of tumor cells were stained with CD45.2 and 
DAPI and collected on the same flow cytometer, using the same settings and gates 
69 
 
as on day 0. The number of eGFP and mCherry cells was calculated based on the 
same gates used on the day of injection. Non-fluorescent cells were ignored for the 
purposes of analysis and the percentage of eGFP and mCherry cells in the tumor 
were normalized to sum to 100%. The fold change in cells expressing each antigen 
was calculated as: (percentage of normalized eGFP cells in tumor) / (percentage of 
eGFP cells at D0).  
 
PresentER minigene cloning and transduction of RMA/S 
The individual PresentER minigenes specified above were cloned into the PresentER 
backbone as previously described78 using the oligonucleotide template 5’- 
GGCCGTATTGGCCCCGCCACCTGTGAGCGGG…[27-30nt 
insert]…TAAGGCCAAACAGGCC-3’ and the table of PresentER constructs above. 
HEK293T Phoenix-Ampho cells were transfected with each plasmid and, after 24h, 
viral supernatant was harvested every 12 hours. RMA/S were transduced with limiting 
amounts of viral supernatant at 1,000xg for 2h at 37ºC in 6 well non-tissue culture 
treated plates. PresentER minigenes vectors are available on Addgene (102942, 
102943, 102944, 102945, 102946). 
 
Library construction in silico 
The peptides included in the libraries were found in Uniprot database of canonical 
mouse protein sequences (UP000000589). Substrings of unique 8 amino acid 
sequences were collected and affinity to H-2Kb was calculated using NetMHCPan 
v4.0. 5,000 randomly selected peptides with predicted ic50<500nM were selected 
and constitute the “wild type peptide library.” A single random amino acid substitution 
was made to each member of the wild type library to generate the “mutant peptide 
library.” Substitutions which generated another wild type peptide were excluded. 
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Library generation in vitro 
Libraries of PresentER minigenes were cloned as previously described78. Library 
metadata is provided as a supplemental file. Oligonucleotide libraries were ordered 
from CustomArray and amplified with Phusion polymerase using pool-specific 
primers: WT library forward 5’-CATGTTGCCCTGAGGCACAG-3’ and reverse 5’-
CGGATCGTCACGCTAGGTAC-3’. Mutant library forward 5’-
GGTCGTCGCATCACAATGCG-3’ and reverse 5’-CGGATCGTCACGCTAGGTAC-3’. 
Library oligonucleotide format: 5’—[pool specific F primer]—
GGCCGTATTGGCCCCGCCACCTGTGAGCGGG—[27-30nt insert]—TAAGGCCAAACAGGCC—[pool 
specific R primer]—3’. Amplicons were digested with SfiI and passed through a MinElute 
column. The PresentER cassette vector was also digested with SfiI, treated with calf 
intestinal phosphatase and ligated to the oligonucleotides with T4 ligase. Ligation 
products were phenol extracted and electroporated into DH5 electrocompetent cells. 
Electroporated cells were plated and counted.  At least 1,000x fold more 
transformants than minigene library members were required to proceed to plasmid 
DNA extraction (>5x106 colonies). The colonies were scraped off the plate and grown 
for 3.5h in TB + ampicillin at 37ºC at 225rpm. The bacteria were maxiprepped using 
the Qiagen maxiprep kit and library representation was checked by Illumina 
sequencing. Library containing retrovirus was produced by transfection of 15cm 
plates of HEK293T Phoenix-AMPHO cells with library plasmid DNA. Viral 
supernatants were collected beginning at 24h after transfection and continuing every 
12 hours until 72 hours post transfection. Viral supernatants were pooled, 
concentrated with Clontech Retro-X concentrator and frozen. Concentrated viral 
supernatant titers were determined by transduction of RMA/S cells. Libraries of 
minigene expressing RMA/S cells were generated by transduction at an MOI < 0.3 
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(1,000xg for 2h at 37ºC in 6 well non-tissue culture treated plates) and selection with 
puromycin. Library expressing cells were maintained in cultures of >1,000x cells per 
number of minigenes in the library (i.e. at least 5x106). 
 
Genomic DNA extraction and minigene sequencing 
To verify that minigene representation was not compromised during cloning, all 
libraries were sequenced from plasmid prior to transduction into mammalian cells. 
Minigenes were either amplified with barcoded primers (P5 F: 5’ 
AATGATACGGCGACCACCGAGATCT 3’; P7 Barcoded R: 5’ 
CAAGCAGAAGACGGCATACGAGATXXXXXXGTGACTGGAGTTCAGACGTGTGCT
CTTCCGATC 3’ and directly submitted for Illumina HiSeq sequencing using a custom 
primer (5’ ACGCTCTTCCGATCTTTGGCCTGTTTGGCCTTA 3’) or they were 
amplified with a non-barcoded, nested PCR protocol (Primer Set #1: F 5’ 
AATGATACGGCGACCACCGAGATCT  3’; R: 5’ 
GTGACTGGAGTTCAGACGTGTGCTCTTCCGATC 3’ and Primer Set #2: F 5’ 
GCCACCTGTGAGCGGG 3’; R: 5’ TCTTTGGCCTGTTTGGCCTTA 3’ ) followed by 
Illumina library preparation and sequencing at the Integrated Genomics Operation at 
MSKCC. Genomic DNA was extracted from cultured cells or mechanically 
disaggregated tumors with the Gentra Puregene kit and minigenes were amplified 
from genomic DNA. Reads were mapped to the PresentER minigene libraries with 
Bowtie2 using default settings. Reads that did not map to the minigenes in the library 
were discarded. Quality control to ensure library representation and absence of 
contamination were performed on every sample. All data analysis was performed in 
R. 
 
Data Availability 
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Sequencing data for each of the experiments has been deposited: 
 
Minigene sequencing of RMA/S tumors expressing libraries of PresentER peptide 
antigen minigenes after 17 days of growth in immunocompetent mice.  
DOI:10.5281/zenodo.1308910 
Minigene sequencing of RMA/S tumors expressing libraries of PresentER peptide 
antigen minigenes after 17 days of growth in immunocompetent mice that were 
either vaccinated or nonvaccinated.  
DOI:10.5281/zenodo.1309837 
Minigene sequencing of RMA/S tumors grown in RAG deficient mice, harvested and 
then transferred and grown in WT or RAG mice. 
DOI:10.5281/zenodo.1310902 
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Results 
PresentER expressing cells recapitulate known T cell immunogenicity 
 
We have developed a method for encoding diverse peptide/MHC (pMHC) ligands in 
mammalian cells (termed “PresentER”) and used this method to perform high-
throughput, pooled screening of MHC-I ligand immunogenicity in wild-type mice. An 
overview and schematic of the cloning strategy, preliminary findings and approach is 
presented in Figure 33. As described Chapter I, The PresentER antigen minigene is 
comprised of an endoplasmic reticulum (ER) signal sequence followed by a short 
peptide/epitope. Expression of the peptide and its display on MHC-I does not require 
proteasomal degradation or peptide processing, thus enabling precise definition of 
the exact epitope displayed to the immune system.  Transporter associated with 
antigen presentation (TAP) deficient cell lines expressing PresentER antigen 
minigenes lead to surface presentation of the encoded MHC-I peptide, detectable by 
multiple modalities, including fluorescently labeled antibodies directed to specific 
MHC-I ligands, mass spectrometry based immunopeptidomics and antigen-specific T 
cell reactivity. To demonstrate the applicability of PresentER antigen minigenes to 
study MHC-I ligand immunogenicity, we first asked if cancer cells encoding known 
immunogenic (mouse gp75 TAYRYHLL W223A,H224Y78; mouse p68 SNFVFAGI 
S551F69; synthetic SIYRYYGL79; synthetic VTFVFAGL68; chicken ovalbumin 
SIINFEKL) or non-immunogenic (mouse PEDF MSIIFFLPL80; scrambled chicken 
ovalbumin FEKIILSN; mouse dEV8 EQYKFYSV82; mouse p68 SNFVSAGI68; mouse 
gp75 TWHRYHLL79; Mouse Trp2 SVYDFFVWL) MHC-I ligands would be rejected by 
wild-type (WT) animals. The C57BL/6 syngeneic, TAP deficient mouse cell line 
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RMA/S was transduced with these antigen minigenes and 5x106 cells were injected 
subcutaneously into WT C57BL6/N mice. Tumors expressing known non-
immunogenic peptides grew, while tumors expressing known immunogenic peptides 
were rejected in some or most animals (Figure 34A). TAP deficient cells were used 
because peptides derived from proteins that are not directed to the ER (e.g. eGFP) 
are not presented on MHC as these cells lack the ability of transport peptide from the 
cytoplasm into the endoplasmic reticulum. 
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Figure 33 Schematic of the cloning strategy of PresentER antigen minigenes 
along with the experiments performed in vivo in this chapter. 
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At 7 days after tumor injection, T cells specific for the chicken ovalbumin peptide 
SIINFEKL could be detected in tumor draining lymph nodes of animals injected with 
PresentER-SIINFEKL expressing cells (Figure 34B). Haemotoxylin and Eosin (H&E) 
staining of regressing PresentER-SIINFEKL tumors showed lymphocytic infiltration 
with hyalin rich fibrin deposits, indicating cell death. By contrast, tumors with 
PresentER-FEKIILSN (a non-MHC-I binding peptide) were well-vascularized, highly 
cellular and with trace lymphocytic infiltration (Figure 34C). In order to verify that the 
mechanism of tumor rejection was indeed T cell dependent, we injected RAG-/- 
animals with SIINFEKL or FEKIILSN positive tumors and confirmed that SIINFEKL 
tumors were not rejected (Figure 34D). Taken together, these results indicate that 
RMA/S tumors expressing PresentER antigen minigenes can recapitulate the known 
immunogenicity of individual mouse MHC-I ligands in a T cell dependent manner. 
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Figure 34 Cells expressing PresentER minigenes recapitulate the known 
immunogenicity of encoded antigens. (A) 5x106 RMA/S cells expressing a 
PresentER minigene were injected subcutaneously into C57BL6/N mice and tumor 
size was monitored by caliper measurements. Top row: WT/non-binding peptide 
minigenes. Bottom row: mutated/foreign peptide minigenes. All plots are compilations 
of several experiments. (B) Mice were injected with 5x106 RMA/S cells expressing 
PresentER-SIINFEKL or PresentER-FEKIILSN. Tumor draining lymph nodes were 
harvested 7 days later and stained with a SIINFEKL/H-2Kb tetramer and CD44. (C) 
H&E staining of tumors expressing PresentER-SIINFEKL or PresentER-FEKIILSN. 
(D) RMA/S PresentER-SIINFEKL and PresentER-FEKIILSN cells were injected into 
RAG-/- mice and tumor growth was monitored. 
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Tumors expressing PresentER antigens do not cause abscopal rejection, but do 
cause subclone fraction-dependent bystander killing 
 
To study immunogenicity in vivo at high throughput and complexity in this model, we 
first wanted to understand if immune responses directed at immunogenic antigens 
lead to rejection of cells presenting non-immunogenic antigens. If so, the ability to 
study immunogenicity in a pooled in vivo setting might be compromised. Mice were 
injected with pairs of tumors expressing an immunogenic and a non-immunogenic 
antigen minigenes (one minigene-expressing tumor on each flank):  
SIINFEKL/FEKIILSN, SIYRYYGL/EQYKFYSV and TAYRYHLL/TWHRYHLL. The 
immunogenic SIINFEKL, SIYRYYGL and TAYRYHLL expressing tumors were 
rejected, but the non-immunogenic FEKIILSN, EQYKFYSV and TWHRYHLL tumors 
found on the contralateral flank were not (Figure 35). This suggests that tumor 
rejection is local and that an effective immune response to an immunogenic tumor 
does not affect the growth of a non-immunogenic tumor.  
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Figure 35 No abscopal effect in the RMA/S antigen minigene tumor model. Mice 
were injected simultaneously with 5x106 RMA/S cells expressing an immunogenic 
PresentER minigene on one flank and a non-immunogenic minigene on the 
contralateral flank: SIINFEKL/FEKIILSN (left; n=3), SIYRYYGL/EQYKFYSV (middle; 
n=5) and TAYRYHLL/TWHRYHLL (right; n=5). Tumor growth curves are shown. 
 
Next, to test if the immune system could identify and kill immunogenic subclones 
within a largely non-immunogenic tumor, we generated tumors with varying ratios of 
immunogenic (SIINFEKL) and non-immunogenic (FEKIILSN) cells. These 
heterogeneous tumors were injected subcutaneously into mice and tumor size was 
monitored. In tumors where PresentER-SIINFEKL cells were greater than 25% of a 
tumor, tumors were smaller and tumor rejection occurred more frequently, especially 
when tumors were comprised of ≥50% immunogenic cells (Figure 36A). Next, we 
wanted to test if immunogenic subclones within a largely non-immunogenic tumor 
could be eliminated. We cloned mCherry into the PresentER vector and mixed 
PresentER-SIINFEKL (mCherry) with non-immunogenic PresentER-MSIIFFLPL 
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(eGFP) cells at varying ratios and injected them into congenically marked CD45.1 
mice. On day 16, the tumors were harvested and flow cytometry was performed to 
identify which (CD45.2 positive) tumor cells remained. Remarkably, within a non-
immunogenic (eGFP labeled) tumor, immunogenic (mCherry labeled) sub-populations 
were eliminated (Figure 36B). Thus, in this model, the immune system is capable of 
recognizing and selectively depleting immunogenic tumor subclones within the 
context of a largely non-immunogenic tumor. 
 
Figure 36 Limited bystander killing of growing tumors in the RMA/S antigen 
minigene tumor model. (A) Mixtures of 5x106 RMA/S PresentER-SIINFEKL and 
PresentER-FEKIILSN injected into wild type mice. Tumor sizes at day 15 are 
presented because some animals had to be sacrificed on day 17. (B) CD45.1+ mice 
were injected with 5 mixtures of PresentER-SIINFEKL (mCherry) and PresentER-
MSIIFFLPL (GFP) cells at several ratios. The top row shows the percentage of 
SIINFEKL and MSIIFFLPL cells at time 0. Tumors were harvested at day 17, 
enzymatically disaggregated and the percentage of CD45.2+ eGFP+ and CD45.2 
mCherry+ cells were quantified (bottom row). The percentage of PresentER-
SIINFEKL cells in each pretumor and tumor sample is highlighted in yellow. The two 
tumors with the highest percentage of PresentER-SIINFEKL cells were complete 
rejected and no cells could be recovered. 
Library screen in vivo reveals the limitations of the immune system to eliminate 
immunogenic tumor subclones 
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We hypothesized that a pooled screen in vivo might reveal the determinants of 
immunogenic MHC-I ligands if a tumor bearing a library of MHC-I antigen were 
depleted of cells bearing immunogenic peptide-MHC while tumor cells bearing non-
immunogenic pMHC were spared (Figure 37A). Using the PresentER system, such a 
screen could be done on large scale and identify hundreds or thousands of 
immunogenic antigens at once, in contrast to identifying immunogenic antigens one-
by-one. Immunoediting in vivo leading to loss of tumor clones with immunogenic 
neoantigen-encoding mutations has previously been observed in syngeneic mouse 
tumor models82-84, suggesting that this approach might be viable. 
 
Figure 37 A drop-out screen for MHC-I peptide immunogenicity in wild type 
mice. Schematic of the drop-out screen for MHC-I immunogenicity. Mice were 
injected with mixtures of RMA/S cells, each of which expresses a different peptide 
that also served as a genetic barcode for later deconvolution. (B) Two libraries of 
mouse MHC-I peptides were constructed. Left: Wild type peptides identified by 
searching the mouse proteome for peptides predicted to bind to MHC-I (NetMHCpan 
H-2Kb ic50 < 500nM). Right: single amino acid mutants of each of the wild type 
peptides. 
 
We searched across all mouse proteins and randomly selected 5,000 8-mer peptides 
that were predicted by NetMHCPan to bind to the B6 mouse MHC-I allele H-2Kb. We 
SNFVSAGI
VVYICHRT
FNFGGFGL
KWYSRFTM
A wild type MHC-I 
peptide library
mutant MHC-I 
peptide library
B
Peptide ic50 (nM) Peptide ic50 (nM)
VSYGFILL 3.2 VSYGWILL 9.3
MFHMYVGV 457.5 MMHMYVGV 71.6
ISYTVVPF 35.2 ISYTEVPF 69
TMQAFAQV 118 TMQAFAMV 133.8
etc… etc…
wild type library mutant library
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also designed a library of mutated peptides by selecting single amino acid 
substituents of each peptide in the wild-type peptide library that did not eliminate 
MHC-I binding (Figure 37B). The MHC-I affinities and properties of the mutated 
peptides are further described in Figure 38. On average, the mutated libraries have 
slightly higher affinity for MHC-I than the wild-type peptides but the plurality of 
mutated peptides are within 100nM of their non-mutated counterparts (Figure 38A-
B). The residues that are changed from the wild-type to the mutant library tend to be 
at positions 4, 6 and 7 (Figure 38C). The majority of mutations are isomorphic 
(polar>polar, hydrophobic>hydrophobic and charged>charged), but ~⅓ of peptides 
feature a hydrophobic>other substitution (Figure 38D). Several known immunogenic 
and known non-immunogenic control antigen minigenes were included in each 
library, including some that were described in Figure 1. The libraries of wild type and 
mutant libraries were separately cloned and introduced into RMA/S cells by 
transduction at multiplicity of infection < 0.3, thereby ensuring that few cells received 
more than one minigene. Naive C57BL6/N mice were injected with either (a) 5x106 
cells expressing the wild type library, (b)  5x106 cells expressing the mutant library, (c) 
5x106 mutant library cells plus 1x106 wild type RMA/S (“padded” to provide a buffer 
against bystander killing in the event that most of the cells in the tumor were 
immunogenic) or (d) 5x106 wild type library cells mixed with 5x106 mutant library cells 
(n=5 per group). The tumors were allowed to grow for 17 days and then harvested 
(Figure 39). Genomic DNA was extracted from all of the tumors, as well as RMA/S 
library cells frozen on the day of injection (“pretumor” samples) and the minigenes 
encoded by each cell were amplified by PCR and sequenced by Illumina next 
generation sequencing. 
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Figure 38 Characteristics of the wild-type and mutated antigen minigene 
libraries. Characteristics of the wild-type and mutated antigen minigene libraries. (A) 
Distribution of MHC-I affinities in the wild-type and mutated library. (B) Difference in 
NetMHCPan predicted H2-Kb affinity (ic50) between wild-type and mutant peptides 
(C) The type of amino acid changes in the mutant library (Polar: Q,N,H,S,T,Y,C,M,W; 
Charged: R,K,D,E; Hydrophobic: A,I,L,F,V,P,G). (D) The positions of the mutations in 
the mutant library with respect to the wild-type 8-mer. 
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Figure 39 Growth curves of RMA/S tumors bearing libraries of PresentER 
minigenes. C57BL6/N mice (n=5 per group) were injected with RMA/S cells 
expressing PresentER libraries: (A) 5x106 WT library cells or 5x106 mutant library 
cells (B) 5x106 mutated peptide library RMA/S cells plus 1x106 untransduced RMA/S 
cells (“padded” mutant peptide library) or 107 wild type library and mutated library 
cells. Tumor growth curves are plotted. 
 
Comparison of minigene abundance in the tumor outgrowth with minigene abundance 
in the pre-tumor samples led to the surprising finding that no minigenes were robustly 
depleted during growth in vivo. (Figure 40). This result stood in stark contrast to the 
experiments described above, in which mutant peptide expressing clones were 
efficiently depleted in immunocompetent mice. Some minigenes that were not 
abundant in the library (<1/10,000) at the time of injection were depleted or dropped 
out entirely in the tumor due simply to stochastic drop-out; however, minigenes that 
were abundant in the library at time of injection maintained their abundance despite in 
vivo growth of the tumor. Surprisingly, even positive control minigenes encoding 
strongly immunogenic peptides (orange points) were not depleted in this context. 
Analysis of minigene abundance in individual animal tumors (as opposed to the 
average of several tumors) yielded the same conclusion that few, if any, minigenes 
were reliably depleted (Figure 41). 
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Figure 40 Abundance of each minigene in RMA/S tumors after growth in vivo. A 
scatter plot showing the average frequency of each minigene in the library before 
injection of the cells (x-axis) and after growth of the tumor in wild type mice (y-axis). 
The abundance of each minigene before injection (n=3) is plotted on the x-axis while 
the abundance of each minigene after 17 days of growth in a wild type mouse is 
plotted on the y-axis (n=5). Orange circles indicate positive control (immunogenic) 
minigenes; blue circles indicate negative control (non-immunogenic) minigenes. The 
straight black lines indicate x=y. LOESS (local best fit) lines are plotted in blue. 
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Figure 41 Abundance of each minigene in each mouse tumor after growth in 
vivo. The abundance of each minigene in each mouse tumor after 17 days of growth 
in vivo (y-axis) compared to the abundance of each minigene in culture (x-axis) 
before injection across four groups of tumors: (A) wild type, (B) mutated, (C) “padded” 
mutated and (D) mixed wild type and mutated peptide libraries. The straight black 
lines indicate x=y.  LOESS (local best fit) lines are plotted in blue. 
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The absolute number of cells at time of injection can be estimated from the relative 
abundance of each minigene in the pre-tumor samples. The least abundant 
minigenes were found at 1 per 5x106 cells (0.00002%) and the most abundant at 
~23x103 per 5x106 (~0.5%). The immunogenic controls SIINFEKL, VTFVFAGL and 
SNFVFAGI were found at 0.005% - 0.013% of cells before injection into mice, which 
correspond to between 250 and 650 cells injected out of 5x106. The number of cells 
expressing the immunogenic antigens upon injection is very low and thus analogous 
to the number of cells that are present during early tumor development, when 
immunogenic transformed cells first arise. The surprising inability of the immune 
system to eliminate these demonstrably immunogenic cells may shed light on the 
limits of immune cell activation and killing during the early stages of tumorigenesis 
that enable outgrowth and escape of immunogenic cancers. 
Vaccination with minigene library does not result in immunosurveillance 
 
A possible explanation for failure of immune surveillance in our RMA/S MHC-I 
minigene library model might be insufficient antigen available in the growing tumor to 
activate an initially productive anti-tumor immune response in naive mice. If this were 
true, we hypothesized that T cells from antigen experienced mice might be able to 
detect and kill immunogenic cells in a highly heterogeneous tumor. Although 
vaccination with soluble peptides has been shown to generate robust T cell 
immunity86,87, this is not cost effective at scale. Alternatively, there is precedence for 
the idea that vaccination with a library of mutated antigens can lead to immunogenic 
T cell responses that lead to slower tumor growth or clearance88. We decided to 
vaccinate mice with irradiated tumor cells bearing the library of MHC-I peptides. In 
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order to avoid confounding immunity to the RMA/S cells themselves89, we used 
CRISPR/Cas9 to generate a B6-syngeic Tap2-/- MCA205 fibrosarcoma cell line. A 
single cell clone of Tap2 knockout MCA205 was selected and Tap2 knockout was 
validated by RT-PCR and next generation sequencing. Decreased surface MHC-I 
staining was expected and observed, because the TAP complex is a key chaperone 
of peptide/MHC-I complex formation (Figure 42).  
 
Figure 42 Generation of an MCA205 TAP deficient cell line. 
MCA205ΔTap2 cell line was generated by transient transfection of MCA205 cells with 
a plasmid encoding Cas9 and an sgRNA directed at Tap2. A single cell clone with an 
INDEL in both alleles of Tap2 was selected and expanded. (A) RT-PCR of genomic 
DNA shows a smaller band than wild-type cells. (B) Left: Loss of surface H2-Kb in the 
ΔTap2 line. Right: transduction of MCA205ΔTAP2 with PresentER-SIINFEKL or 
PresentER-MSIIFFLPL and staining with SIINFEKL/H2-Kb TCR mimic antibody shows 
ER independent presentation of the SIINFEKL antigen. (C) Next generation sequence 
of the MCA205ΔTap2 single cell clone shows two different 28bp deletions in both Tap2 
loci. 
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WT B6 mice were vaccinated three times, once every 5 days, with 1x107 irradiated 
MCA205∆Tap2 cells bearing the wild-type library minigenes (Figure 43A). 
Splenocytes and draining lymph nodes from three vaccinated and three non-
vaccinated mice were examined at day 17 after the final vaccination and analyzed for 
the presence of antigen experienced T cells. Five control peptide tetramers were 
used, three of which are immunogenic and were present in the library (SIINFEKL, 
SNFVFAGI, VTFVFAGL), one which is not immunogenic but was present in the 
library (MSIIFFLPL) and one which is immunogenic but not found in the library 
(SIYRYYGL). Only the immunogenic peptides found in the library showed an 
increased number of CD44+/tetramer+ CD8 T cells, while the other two peptides did 
not show significant changes (Figure 43B). Therefore, vaccination with the library 
yielded detectable specific T cell populations to the immunogenic peptides. 
Vaccinated and non-vaccinated mice were then challenged with 5x106 RMA/S cells 
bearing the wild type peptide library.  Slower tumor growth was noted in the 
vaccinated as compared to the non-vaccinated mice, suggesting that a vaccine-
related anti-tumor effect may have occurred (Figure 43C). However, neither 
vaccinated nor unvaccinated animals showed depletion of immunogenic control 
minigenes in relation to the non-immunogenic control minigenes (Figure 44). Thus, 
although slower tumor growth was noted, antigen-specific immunity was not observed 
in response to prophylactic vaccination in the library setting, suggesting a possible 
response to some other, broadly expressed, cellular antigens not represented in the 
peptide library. 
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Figure 43 Vaccination of wild type mice with minigene library-expressing 
MCA205ΔTap2 cells leads to increased antigen-reactive T cells. Schematic of the 
vaccinations performed on C57BL/6N mice. 107 Irradiated MCA205ΔTap2 cells 
expressing wild type library peptides were injected subcutaneously every six days (for 
a total of three vaccinations). On day 18, three mice from each group were sacrificed 
for tetramer analysis. Draining lymph nodes and splenocytes were stained with H-2Kb 
peptide tetramers.  At day 18, five mice were challenged with 5x106 RMA-S cells 
expressing the library. (B) Splenocytes and draining lymph node cells from 
vaccinated animals were stained for CD8, CD44, and H-2Kb/peptide tetramers. Five 
control peptides were evaluated: 4 found in the library and 1 peptide not found in the 
library. The frequency of CD44/tetramer positive CD8 cells is reported. (C) Growth 
curves of RMA/S library tumors in in vaccinated or unvaccinated mice. 
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Figure 44 Vaccination of wild type mice with minigene library-expressing 
MCA205ΔTap2 cells does not increased immune surveillance. Average 
abundance of each minigene (n=5 unvaccinated mice and n=4 vaccinated mice) in 
cultured cells before injection into mice (x-axis) compared to minigene abundance in 
tumors harvested from vaccinated (y-axis) (A) or non-vaccinated (y-axis) (B) mice. 
Each circle is a minigene. Orange circles indicate positive control (immunogenic) 
minigenes; blue circles indicate negative control (non-immunogenic) minigenes.  (C) 
Direct comparison of minigene abundance in tumors grown in vaccinated and non-
vaccinated animals. The straight black lines indicate x=y. LOESS (local best fit) lines 
are plotted in blue. 
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Rejection of immunogenic subclones depends on subclone fraction in tumor 
 
While we have demonstrated that PresentER minigenes peptides can generate 
effective antigen-specific immunogenicity in bulk RMA/S tumor assays, the same 
response does not occur in tumors bearing libraries of MHC-I ligands. In order to test 
if there is a threshold level of tumor cell clonality necessary to effectively activate the 
immune system, CD45.1 mice were injected with mixtures of immunogenic (labeled 
with eGFP) and non-immunogenic (labeled with mCherry) RMA/S cells and flow 
cytometry was performed on reisolated tumors 17 days later (). Relative to their 
proportion upon engraftment, tumor cells bearing the immunogenic peptides 
SIINFEKL and TAYRYHLL were depleted when they comprised as little as 1% of the 
tumor. Below 1%, depletion of cells bearing these two minigenes could not be 
detected. Depletion of cells bearing the SNFVSAGI peptide could be reliably detected 
at 50% and in some tumors at 10%, however depletion could not be detected when 
the SNFVSAGI cells were found at less than 10% of the tumor (Figure 45). These 
findings are surprising, as they indicate that immunogenic tumor subclones can 
persist within a tumor and that rejection or persistence is dependent on tumor cell 
percentage of the total tumor mass during tumorigenesis, and not immunogenicity of 
the cell alone. 
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Figure 45 Immunosurveillance fails when tumor subclone frequency is low. (A) 
Schematic and (B) results of experiments to detect antigen-specific immune 
surveillance thresholds. CD45.1+ C57BL/6N mice were injected with mixtures of 
immunogenic and non-immunogenic RMA/S cells. Mixtures were 50%, 90%, 99% or 
99.9% non-immunogenic PresentER-MSIIFFLPL (mCherry) mixed with 50%, 10%, 
1% or 0.1% cells expressing one of three different immunogenic minigenes (eGFP) 
noted in the inset. After 17 days in the mouse, tumors were enzymatically 
disaggregated, stained with CD45.2 and analyzed by flow cytometry. t-tests with the 
alternative hypothesis that log10 fold change is 0 were performed for each group. 
Some tumors were rejected entirely and these were excluded from the presented 
depletion analysis. At least 3 tumors per group yielded sufficient numbers of cells to 
be confident that depletion had occurred. All groups marked with 4 stars reached a p-
value of <0.001. 
 
Failure of the immune system to eliminate immunogenic subclones present at low 
fractional abundance could either be due to the low quantity of total antigen present in 
the tumor or to the low percentage of cells bearing each antigen. In order to 
discriminate between these two possibilities, we increased the amount of tumor 
injected, thus increasing the total amount of antigen the immune system sees while 
keeping the percentage of each antigen within the tumor the same. We grew RMA/S 
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library tumors in RAG-/- mice, harvested the tumors at 20 days and retained a portion 
of the material for sequencing. The rest of the tumor material was transferred into the 
flank of WT B6 or RAG-/- mice. Each animal received approximately 1 milliliter of 
tumor fragments (~2.5x108 cells), which represents a 40-100 fold increase in cells 
expressing each antigen (Figure 46A). After 17 days, the transferred tumors were 
harvested and sequenced. Once again, as we observed in both naive and vaccinated 
mice, robust depletion of immunogenic minigene peptides did not occur. Overall 
minigene abundance was highly correlated between the tumor material transferred 
and the tumors harvested 17 days later in both WT and RAG-/- mice and in both the 
wild type and mutant libraries (Figure 46B). These results reveal that it is the 
percentage of tumor cells bearing each antigen within a tumor and not the total 
quantity of antigen that determines if an effective immune response occurs. 
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Figure 46 Large numbers of tumor cells do not overcome failure of 
immunosurveillance when tumor subclone frequency is low. (A) In order to 
overcome the hypothesized lack of immune surveillance at low minigene abundance, 
2 RAG-/- mice were injected at 4 sites with 5x106 RMA/S library cells per site. Tumors 
were harvested after 20 days, minced and pooled. Approximately 1mm3 of tumor 
fragments were implanted subcutaneously into the flank of either wild-type or RAG-/- 
mice and allowed to grow for 17 days. (B) The abundance of each minigene (average 
of 3 mice) in tumors transferred to WT mice (y-axis) compared to tumors transferred 
to RAG-/- mice (x-axis) is plotted. Each circle is a minigene. Orange circles indicate 
positive control (immunogenic) minigenes; blue circles indicate negative control (non-
immunogenic) minigenes. The straight black lines indicate x=y. LOESS (local best fit) 
lines are plotted in blue. 
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Discussion 
 
The immune system is capable of recognizing cancer cells as foreign based on the 
presentation of altered or unusual MHC-I ligands on the surface of tumor cells—a 
phenomenon that has been leveraged for cancer therapy such as immune checkpoint 
blockade and adoptive cell transfer19,21,66. Despite this recognition, the immune 
system fails to clear these immunogenic, clinically detected tumors on its own, as has 
been paradoxically noted for decades67. It is not clear at what point in tumorigenesis 
the immune system begins to initiate (ineffectively) a response to immunogenic MHC-
I ligands presented on cancer cells. There is epidemiologic evidence that 
immunocompromised patients develop more tumors, suggesting that the immune 
system may prevent some tumors (mostly virally driven) from ever manifesting 
clinically by effective immunosurveillance. However, recent data also suggests that 
mutations accumulate at high rates in sun-damaged, but otherwise normal, tissue at 
levels comparable to cancer cells90 and that tumors face overall little negative 
selective pressure91. Indeed, immune escape by loss of MHC 92-96, when it occurs, is 
a late and subclonal event97,98. If T cell surveillance were highly effective during early 
tumor development, negative selective pressure would be notable in the evolutionary 
trajectories of tumors and HLA loss would be expected to occur early, frequently and 
in a clonal manner. We interpret the data from human and animal experiments to 
suggest that routine T cell immunosurveillance of nascent cancer cells does occur, 
but is limited by unknown factors and that recognition of tumors as foreign occurs 
mostly later in tumor development. 
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If tumor immunosurveillance is sometimes effective in the early growth of a tumor, we 
hypothesized that it might be due to potent neoantigens expressed by cancer cells. 
Discovery of the biochemical characteristics of mutationally-derived neoantigens that 
are immunogenic would be important to clarify why some neoantigens are tolerated 
by the immune system and others are not. The significance of this question is 
underscored by the major challenge currently facing cancer immunotherapy: the 
identification of patients whose tumors bear immunogenic neoantigens—and are thus 
likely to respond well to immune checkpoint blockade or other immunotherapies—vs 
those patients who will be unnecessarily exposed to potentially toxic therapies without 
a chance for efficacy. 
 
Here, we have developed a reductionist approach to determine which MHC-I ligands 
are immunogenic in immunocompetent mice. We demonstrate that tumors are 
rejected when an immunogenic pMHC is expressed on all or most injected cancer 
cells. To our surprise, we have discovered that effective T cell responses are not 
mounted against highly immunogenic peptides when cells expressing these peptides 
are a minor fraction of the tumor, which is the case in early developing tumors in 
humans. Furthermore, the threshold percentage of tumor cells necessary to yield an 
antigen-specific immunogenic T cell response varies with the antigen. We propose 
that ineffective T cell responses may be a consequence of intratumoral (or intra-
tissue) heterogeneity and that neoantigen clonal fraction is an important, overlooked 
aspect of MHC-I antigen immunogenicity. 
 
There are many mechanisms by which immune mediated killing of immunogenic 
cancer cells can fail. Here we report the first evidence that tumor heterogeneity is an 
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explicit factor leading to failure of effective immunity in a tumor and that the maximum 
level of heterogeneity tolerable before immune escape occurs is dependent on the 
antigen. Immune checkpoints or active tumor suppression do not explain the 
observed immune evasion because such mechanisms would be expected to 
suppress T cell killing irrespective of the fraction of tumor cells that expresses an 
immunogenic epitope and might be even more effective for minor subclones. This is 
evidenced by robust depletion of the highly immunogenic peptides SIINFEKL and 
TAYRYHLL when present at ≥1% of the tumor. The mechanism by which T cell 
responses are restrained when immunogenic MHC-I antigens are present at low 
frequency is not yet clear. Low levels of antigen presentation may lead to ineffective 
cross-presentation of antigen in the tumor draining lymph node, thus limiting T cell 
activation99. Moreover, in animal models, low levels of immunogenic epitopes of 
oncogenic drivers presented on transformed cells early during tumorigenesis (at the 
premalignant stage) were shown to induce a program of cellular hypo-responsiveness 
in tumor-specific (oncogene-specific) CD8 T cells 100,101. After prophylactic vaccination 
with irradiated library cells we observed increased numbers of antigen-specific T cells 
in splenocytes and draining lymph nodes, suggesting that some antigen-specific T 
cell proliferation does occur, but it does not lead to a productive anti-tumor response. 
We speculate that the mechanism of immune escape in this model is either ineffective 
T cell activation or failure of activated T cells to identify and kill antigen-positive cells 
present at low abundance within a sea of cells displaying irrelevant antigens. 
 
New therapeutic modalities such as immune checkpoint blockade have shown clinical 
efficacy in the treatment of human tumors, but the toxicity of the drug regimens has 
led to many efforts to find biomarkers that predict patient response. Tumors with high 
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mutation burdens—which are more likely to have immunogenic neoantigens102-104—
and tumors that have mismatch repair (MMR) deficiency or microsatellite instability 
(MSI-H) respond well to checkpoint blockade105,106. In mouse models, syngeneic 
tumors with MMR gene knock outs accumulate mutations over time and grow more 
slowly in wild type mice than do tumors without MMR deficiency. Cell lines derived by 
sub-cloning of MMR deficiency lines—thus increasing the clonal fractions of each 
neoantigen—grow more slowly or are rejected entirely. In all cases, MMR inactivation 
in tumors leads to better responses to checkpoint blockade than the parental 
tumors107. Moreover, survival is inversely related to tumor neoantigen clonality in 
human patients with lung adenocarcinoma74,75. Patients whose tumors bear high 
numbers of subclonal (or branched) neoantigens have increased levels of relapse 
and worse survival than those patients with more homogenous tumors74,75. Response 
to checkpoint blockade in lung and skin tumors is also associated with lower levels of 
intratumoral heterogeneity74. The combination of these data are highly suggestive that 
while total neoantigen burden is important for long term survival and response to 
checkpoint blockade, neoantigen clonality is an additional important factor in 
mediating tumor regression. 
 
The discovery that intratumoral heterogeneity prevents effective T cell responses has 
implications for the development of therapeutic cancer vaccines, checkpoint 
blockade, adoptive T cell therapies, and studies of tumor immunogenicity. In addition, 
our data may provide a new understanding of mechanisms of immune surveillance 
and its failure that allows growth and evolution of tumors and subclones. For 
instance, recent data shows that subclones with very low clonal fraction yet distinct 
intratumoral functions may be important to tumor survival and growth108—suggesting 
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that even low abundance tumor subclones may be important targets for 
immunotherapy. In general, we may speculate on one mechanism for cancer escape 
and progression, in which small early cancers generally do not bear immunogenic 
epitopes derived from their limited number of driver oncogenic proteins and few 
passenger mutations. Then as the tumors evolve, the potential neoantigens 
appearing in subclones may not reach a clonal fraction high enough to breach their 
antigen-specific immunogenicity thresholds, thereby allowing escape of these 
otherwise immunogenic clones. This model may help to explain why sun-damaged 
and aged healthy tissue is replete with mutations, sometimes reaching frequencies 
seen in human cancers90,109. Cumulatively, these findings suggest that effective T cell 
immunity is restrained in the context of healthy tissue and growing tumors and paint a 
picture of T cell immunogenicity that is poorly captured by existing models of tissue 
immunosurveillance. 
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Thesis Summary 
PresentER is a method to identify the targets of T cells and TCR like molecules 
Here, we describe a new retroviral minigene that leads to the surface expression of a 
precisely defined, genetically encoded MHC-I ligand. The minigene is capable of 
driving antigen presentation from only a single inserted copy of the retroviral vector, 
thus enabling its use in pooled screens. Using a library of >12,000 MHC-I ligands 
derived from digestion in silico of the human proteome, we screened two soluble TCR 
mimic antibodies against cells expressing this library. We identified hundreds of 
cross-reactive ligands, some of which were known to be HLA-A*02:01 peptides 
presented on real tissue. Several of these cross-reactive ligands were not predictable 
from the initial characterization of the off-targets of these antibodies.  
 
To extend the use of PresentER to membrane bound TCR present on T cells, we first 
confirmed that T cells bearing antigen-specific TCR could kill cells expressing their 
target antigen using the PresentER minigene. Then, we generated a library of 5,000 
peptides derived from digestion in silico of the human proteome and based on the 
known binding specificities of the A6 and B7 TCR. These TCR were screened against 
the library, re-confirming 70-80 and 40, respective, single amino acid substituted 
targets of these TCRs. 
 
Given the large number of TCR-based therapeutics that are in the pre-clinical or early 
clinical trial phase, there is pressing need for a method that can be used to 
systematically identify the off-targets of TCR like agents. Several patients treated with 
these agents have already died from cross-reactivities31,110 that are potentially 
identifiable before treatment. 
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Future Directions 
Identification of targets of Tumor Infiltrating Lymphocytes 
One long-standing question in the field of cancer immunology is: what are the targets 
of tumor infiltrating lymphocytes (TILs)? We have demonstrated that the targets of 
TCR can be discovered using PresentER screening. We propose that the targets of 
bulk tumor infiltrating lymphocytes could also be discovered by co-culture of these 
cells with libraries of cells bearing patient-specific neoantigens. Most human cancers 
have between 1,000 and 30,000 somatic mutations111. Assuming 20 peptides can be 
derived from each mutation and ~5% of these will bind to one or more of the patient’s 
HLA alleles, the number of mutations that must be tested is approximately equal to 
the number of somatic changes in the patient’s cancer. This number is well within the 
range of peptides that can be tested in a patient-specific manner.  
Degenerate libraries of MHC-I ligands 
Biased libraries of MHC-I peptides that have been informed by pre-existing 
information about the targets of T cells are useful for discovery of off-targets. 
However, the ability to identify the targets of T cells without any pre-existing 
information about what the target might look like would be a major advance. We 
propose that relatively small libraries of PresentER encoded MHC-I peptides could be 
used to identify the key pairs of residues that a cloned TCR reacts to. For instance, 
the number of 9-mer peptides where the 2nd and 9th amino acid are fixed as Leu1 and 
Val9 (to ensure HLA-A*02:01 binding) and the 6th or 7th amino acid is fixed as a 
leucine, and all other positions are varied, is only ~10,000 peptides. Such a small 
library might be able to identify key residues that a TCR needs to engage with its 
target, thus enabling the rapid identification of the actual target of the TCR. 
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PresentER can be used to study the immunogenicity of MHC-I presented 
antigens in vivo, but rejection of immunogenic tumor clones is limited by clonal 
fraction  
What makes one foreign/mutated MHC-I ligand immunogenic and another tolerated? 
This is a fundamental question in T cell immunology that we thought we might be able 
to answer using the PresentER antigen minigene system. We first showed that 
previously known immunogenic MHC-I peptides could mediate tumor rejection in wild 
type, immunocompetent mice while non-immunogenic peptides were tolerated and 
allowed tumor outgrowth. We next showed that the immune rejection was specific to 
cells within the tumor that expressed the immunogenic peptide. Finally, we cloned 
libraries of WT and mutated mouse MHC-I ligand libraries and grew tumors bearing 
thousands of distinct peptides in mice, only to find no robust elimination of even the 
highly immunogenic control peptides found in the tumor libraries. By making carefully 
defined heterogeneous tumors of comprised of 0.1-50% immunogenic cells, we were 
able to show that the fraction of cells expressing an immunogenic antigen must be 
greater than an antigen-specific threshold in order to see immune-mediated 
elimination. This unexpected finding has implications for the consideration of 
neoantigen heterogeneity in human cancers during tumorogenesis and is consistent 
with pre-existing data showing that clinical outcomes are worse for patients with 
highly heterogeneous tumors compared to those with homogenous tumors. Failure of 
the immune system to control immunogenic tumor subclones may be a part of the 
explanation for the poor outcomes in these patients. 
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We were unable to identify which MHC-I peptides are immunogenic when growing 
subcutaneous tumors with thousands of distinct MHC-I ligands within WT mice 
because the clonal fraction needed for depletion is, at minimum, 1% (in the two most 
immunogenic antigens we studied). Even relatively small libraries of 100 peptides 
might fail to identify immunogenic peptides based on the thresholds we have 
examined. As a result, we believe that at least in the context of solid, subcutaneous 
tumors, the ability to identify immunogenic peptides will remain limited. Introduction of 
tumors into mice by other methods, such by IV injection led to death of treated mice 
within days (data not shown). However, we have not yet tried placing the tumor cells 
in the IP cavity of a mouse, which might lead to the growth of many small patches of 
tumor cells, some of which may be well recognized by antigen-specific T cells. 
 
Alternatively, now that we have demonstrated the ability of libraries of cells to be 
depleted by T cells in vitro, it might be possible to identify immunogenic cells by 
stimulating antigen-specific T cells in vitro (perhaps using libraries expressed by 
MCA205∆Tap2 cells) and then co-culturing these cells with RMA/S libraries (or vice 
versa). These kinds of approaches might allow the systematic identification of 
immunogenic neoantigens, a goal of critical importance in the field of T cell 
immunology. 
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